]> C50.0 Nipple C50.1 Central portion of breast C50.2 Upper-inner quadrant of breast C50.3 Lower-inner quadrant of breast C50.4 Upper-outer quadrant of breast C50.5 Lower-outer quadrant of breast C50.6 Axillary Tail of breast C50.8 Overlapping lesion of breast C50.9 Breast, NOS Note: Laterality must be coded for this site. CS Tumor Size Note 1: Code the specific tumor size as documented in the medical record. If the only information regarding tumor size is the physician's statement of the T category, assign code 990 (T1mi), 991 (T1b), 992 (T1 or T1c), or 995 (T2). If the physician's statement of the T category is T1a with no documentation of tumor size, code tumor size as 005. If the physician's statement of the T category is T3 with no documentation of tumor size or a statement specifying only that the tumor size is greater than 5 cm, code tumor size as 051. Note 2: When coding pathologic size, code the measurement of the invasive component. For example, if there is a large in situ component (e.g., 4 cm) and a small invasive component, see CS Site-Specific Factor 6 to code more information about the reported tumor size. If the size of invasive component is not given, code the size of the entire tumor and record what the size value represents in CS Site-Specific Factor 6. Note that some breast cancers cannot be sized pathologically. Note 3: Microinvasion is the extension of cancer cells beyond the basement membrane into the adjacent tissues with no focus more than 0.1 cm in greatest dimension. When there are multiple foci of microinvasion, the size of only the largest focus is used to classify the microinvasion. (Do not use the sum of all the individual foci.) Code Description 000 No mass/tumor found 001-988 989 989 mm or larger 990 991 992 993 Described as "less than 3 cm," or "greater than 2 cm," or "between 2 cm and 3 cm" 994 Described as "less than 4 cm," or "greater than 3 cm," or "between 3 cm and 4 cm" 995 996 997 998 Diffuse 999 CS Extension Note 1: Changes such as dimpling of the skin, tethering, and nipple retraction are caused by tension on Cooper's ligament(s), not by actual skin involvement. They do not alter the classification. Note 2: Consider adherence, attachment, fixation, induration, and thickening as clinical evidence of extension to skin or subcutaneous tissue, code 200. Note 3: Consider fixation, NOS as involvement of pectoralis muscle, code 300. Note 4: If CS Extension code is 000, then Behavior code must be 2; if CS Extension code is 050 or 070, then Behavior code may be 2 or 3; and if CS Extension code is 100, then Behavior code must be 3. Note 5: Inflammatory Carcinoma: AJCC includes the following text in the Cancer Staging Manual 7th Edition: "Inflammatory carcinoma is a clinicopathologic entity characterized by diffuse erythema and edema (peau d'orange) of the breast, often without an underlying palpable mass. These clinical findings should involve the majority of the skin of the breast. Classically, the skin changes arise quickly in the affected breast. Thus the term of inflammatory carcinoma should not be applied to a patient with neglected locally advanced cancer of the breast presenting late in the course of her disease. On imaging, there may be a detectable mass and characteristic thickening of the skin over the breast. This clinical presentation is due to tumor emboli within dermal lymphatics, which may or may not be apparent on skin biopsy. The tumor of inflammatory carcinoma is classified T4d. It is important to remember that inflammatory carcinoma is primarily a clinical diagnosis. Involvement of the dermal lymphatics alone does not indicate inflammatory carcinoma in the absence of clinical findings. In addition to the clinical picture, however, a biopsy is still necessary to demonstrate cancer either within the dermal lymphatics or in the breast parenchyma itself." Note 6: For CS coding, the abstractor should record a stated diagnosis of inflammatory carcinoma, and also record any clinical statement of the character and extent of skin involvement in the text area. Code 600 should be used if there is a stated diagnosis of inflammatory carcinoma and a clinical description of the skin involvement is less than one-third (33%) of the skin of the breast. Code 725 should be used if there is a stated diagnosis of inflammatory carcinoma and a clinical description of the skin involvement is greater than or equal to one-third (33%) and less than or equal to one-half (50%) of the skin of the breast. Code 730 should be used if there is a stated diagnosis of inflammatory carcinoma and a clinical description of the skin involvement in more than one-half (50%) (majority or diffuse) of the skin of the breast. Cases with a stated diagnosis of inflammatory carcinoma but no such clinical description should be coded 750. A clinical description of inflammation, erythema, edema, peau d'orange, or other terms describing skin changes without a stated diagnosis of inflammatory carcinoma should be coded 512-585 depending on described extent of the condition. Code Description TNM 7 Map TNM 6 Map SS77 Map SS2000 Map 000 Tis Tis IS IS 050 Tis Tis ** ** 070 Tis Tis ** ** 100 ^ * L L 110 ^ * L L 120 ^ * L L 130 ^ * L L 140 ^ * L L 170 Stated as T1 [NOS] with no other information on extension or size T1NOS T1NOS L L 180 Stated as T2 with no other information on extension or size T2 T2 L L 190 Stated as T3 with no other information on extension or size T3 T3 L L 200 ^ * RE RE 300 ^ * RE RE 380 ERROR ERROR ERROR ERROR 390 ERROR ERROR ERROR ERROR 400 T4a T4a RE RE 410 Stated as T4a with no other information on extension T4a T4a RE RE 510 ERROR T4b RE RE 512 T4b T4b RE RE 514 T4b T4b RE RE 516 514 + 512 T4b T4b RE RE 518 T4b T4b RE RE 519 518 + 512 T4b T4b RE RE 520 T4b T4b RE RE 575 520 + 512 T4b T4b RE RE 580 T4b T4b RE RE 585 580 + 512 T4b T4b RE RE 590 ERROR ERROR ERROR ERROR 600 T4b T4d RE RE 605 T4b T4b RE RE 610 ERROR T4c RE RE 612 Any of (512-516) + 400 T4c T4c RE RE 613 Any of (518-519) + 400 T4c T4c RE RE 615 Any of (520-585) + 400 T4c T4c RE RE 620 ERROR T4c RE RE 680 Stated as T4c with no other information on extension T4c T4c RE RE 710 ERROR T4d RE RE 715 T4b T4d RE RE 720 ERROR ERROR ERROR ERROR 725 T4d T4d RE RE 730 T4d T4d RE RE 750 T4d T4d RE RE 780 Stated as T4d with no other information on extension T4d T4d RE RE 790 Stated as T4 [NOS] with no other information on extension T4NOS T4NOS RE RE 950 No evidence of primary tumor T0 T0 U U 999 TX TX U U ^ For CS Extension codes 100-140, 200, and 300 ONLY, the T category is assigned based on value of CS Tumor Size as shown in the Extension Size Table for this schema. * For CS Extension codes 100-140, 200, and 300 ONLY, the T category is assigned based on value of CS Tumor Size as shown in the Extension Size Table for this schema. ** For CS Extension codes 050 and 070 ONLY, Summary Stage 1977 and Summary Stage 2000 are assigned based on the value of Behavior Code ICD-O-3 as shown in the Extension Behavior Table for this schema. &generalcstsexteval; CS Lymph Nodes Note 1: Code only regional nodes and nodes, NOS, in this field. Distant nodes such as cervical (excluding supraclavicular) or contralateral axillary are coded in CS Mets at DX. Note 2: Micrometastases are defined as tumor deposits greater than 0.2 millimeter (mm) but not greater than 2.0 mm in largest dimension. Macrometastases are tumor deposits greater than 2.0 mm. All nodes with at least micrometastases are included in the count of positive lymph nodes, but at least one node must contain a macrometastasis for assignment of a pathologic N category greater than pN1mi. Note 3: If the pathology report indicates that nodes are positive but size of the metastases is not stated, assume the metastases are greater than 0.2 mm and code the lymph nodes as positive in this field. Use code 600 in the absence of other information about regional nodes. Note 4: In a physical exam if palpable nodes are not described as fixed or matted, assume that nodes are movable. Note 5: Codes 130-600 refer to level I and level II ipsilateral axillary lymph nodes and ipsilateral intramammary nodes only. Ipsilateral level III axillary lymph nodes, which are also known as infraclavicular or apical nodes, are coded 750 or higher. Axillary lymph nodes do not include internal mammary or ipsilateral supraclavicular lymph nodes. Note 6: For the breast schema, the choice of the N category is dependent on the CS Lymph Nodes Eval field. There are certain CS Lymph Nodes codes that can only be used if the nodes are evaluated clinically (CS Lymph Nodes Eval is coded 0, 1, 5, or 9), which will be designated as "Evaluated clinically:" at the beginning of the code description. Similarly, there are certain CS Lymph Nodes codes that can only be used if the nodes are evaluated pathologically (CS Lymph Nodes Eval is coded 2, 3, 6, or 8), and these will be designated as "Evaluated pathologically:". All other codes can be used for clinical or pathologic evaluation. Note 7: Isolated tumor cells (ITC) are defined as single tumor cells or small clusters not greater than 0.2 mm, usually detected only by immunohistochemical (IHC) or molecular methods but which may be verified on hematoxylin and eosin (H and E) stains. ITCs do not usually show evidence of malignant activity (e.g., proliferation or stromal reaction). Lymph nodes with ITCs only are not considered positive lymph nodes. If the record only states N0(i+), code to 000 and see CS Site-Specific Factor 4. Code Description TNM 7 Map TNM 6 Map SS77 Map SS2000 Map 000 ^ * NONE NONE 050 N0(i+) N0(i+) NONE NONE 130 N1mi N1mi RN RN 150 N1mi N1mi RN RN 155 N1mi N1mi RN RN 250 ^^ ** RN RN 255 N1 N1 RN RN 257 N1 N1 RN RN 258 ^^ ** RN RN 260 Stated as N1 [NOS] with no other information on regional lymph nodes ^^ ** RN RN 280 ERROR ** RN RN 290 ERROR ERROR ERROR ERROR 300 ERROR ERROR ERROR ERROR 500 ERROR ** RN RN 510 ^^ ** RN RN 520 ^^ ** RN RN 600 ^^ ** RN RN 610 ^^ ** RN RN 620 ^^ ** RN RN 630 ^^ ** RN RN 710 N1b N1b RN RN 720 ^^ ** RN RN 730 N1b N1b RN RN 735 N2b N2b RN RN 740 N2b N2b RN RN 745 N2b N2b RN RN 748 ^^ ** RN RN 750 N3a N3a D RN 755 N3a N3a D RN 760 N3b N3b RN RN 763 N3b N3b RN RN 764 N3b N3b D RN 765 N3b N3b D RN 768 N3b N3b RN RN 770 ERROR N2b RN RN 780 ERROR N3a D RN 790 ERROR ERROR ERROR ERROR 800 Supraclavicular node(s), ipsilateral N3c N3c D D 805 N3c N3c D D 810 N3NOS N3NOS RN RN 815 N3NOS N3NOS RN RN 820 N3NOS N3NOS RN RN 999 NX NX U U ^ For CS Lymph Nodes code 000 ONLY, the N category is assigned based on the coding of CS Site-Specific Factors 4 and 5 using the IHC MOL Table for this schema. ^^ For CS Lymph Nodes codes 250, 258, 260, 510, 520, 600, 610, 620, 630, 720, and 748 ONLY, the N category is assigned based on the values of CS Lymph Nodes Eval and CS Site-Specific Factor 3 (Number of Positive Ipsilateral Axillary Lymph Nodes). If the CS Lymph Nodes Eval code is 2 (p), 3 (p), 6 (yp), or 8 (a), the N category is determined by reference to the Lymph Nodes Pathologic Evaluation Table. If the CS Lymph Nodes Eval code is 0 (c), 1(c), 5(c), or 9 (c), the N category is determined by reference to the Lymph Nodes Clinical Evaluation Table. If the CS Lymph Nodes Eval field is not coded, the N category is determined by reference to the Lymph Nodes Positive Axillary Node Table. * For CS Lymph Nodes code 000 ONLY, the N category is assigned based on the coding of CS Site-Specific Factors 4 and 5 using the IHC MOL Table for this schema. ** For CS Lymph Nodes codes 250,258, 260, 280, 500, 510, 520, 600, 610, 620, 630, 720, and 748 ONLY, the N category is assigned based on the values of CS Lymph Nodes Eval and CS Site-Specific Factor 3 (Number of Positive Ipsilateral Axillary Lymph Nodes). If the CS Lymph Nodes Eval code is 2 (p), 3 (p), 6 (yp), or 8 (a), the N category is determined by reference to the Lymph Nodes Pathologic Evaluation Table. If the CS Lymph Nodes Eval code is 0 (c), 1(c), 5(c), or 9 (c), the N category is determined by reference to the Lymph Nodes Clinical Evaluation Table. If the CS Lymph Nodes Eval field is not coded, the N category is determined by reference to the Lymph Nodes Positive Axillary Node Table. &generalregnodeseval; Regional Nodes Positive Note 1: Record this field even if there has been preoperative treatment. Note 2: Lymph nodes with only isolated tumor cells (ITCs) are NOT counted as positive lymph nodes. Only lymph nodes with metastases greater than 0.2mm (micrometastases or larger) should be counted as positive. If the pathology report indicates that nodes are positive but size of the metastases is not stated, assume the metastases are > 0.2mm and code the lymph nodes as positive in this field. Note 3: Record all positive regional lymph nodes in this field. Record the number of positive ipsilateral regional level I-II axillary nodes separately in the appropriate Site-Specific Factor field. Code Description 00 All nodes examined negative. 01-89 1 - 89 nodes positive (code exact number of nodes positive) 90 90 or more nodes positive 95 Positive aspiration or core biopsy of lymph node(s) 97 Positive nodes - number unspecified 98 No nodes examined 99 &generalreglnexam; CS Mets at DX Note 1: Involvement of supraclavicular (transverse cervical) lymph nodes is coded in CS Lymph Nodes. Note 2: Cases in which there are no distant metastases as determined by clinical and/or radiographic methods are designated cM0 (use code 00). Cases in which one or more distant metastases are identified by clinical and/or radiographic methods are designated cM1. A case is classified as clinically free of metastasis (cM0) unless there is documented evidence of metastasis by clinical means or by biopsy of a metastatic site (pathologic). Use code 99 if there is no documentation available for any staging assessment, or if there is reasonable doubt that the tumor is no longer localized and there is no documentation of distant metastasis. Code Description TNM 7 Map TNM 6 Map SS77 Map SS2000 Map 00 No distant metastasis M0 M0 NONE NONE 05 No clinical or radiographic evidence of distant metastasis, but deposits of molecularly or microscopically detected tumor cells in circulating blood, bone marrow or other non-regional nodal tissue that are 0.2 millimeters (mm) or less in a patient without symptoms or signs of metastasis M0(i+) M0 NONE NONE 07 Stated as M0(i+) with no other information on distant metastasis M0(i+) M0 NONE NONE 10 M1 M1 D D 40 M1 M1 D D 42 M1 M1 D D 44 M1 M1 D D 50 M1 M1 D D 60 M1 M1 D D 99 M0 MX U U &generalmetseval; CS Site-Specific Factor 1 Estrogen Receptor (ER) Assay Note 2: In general, estrogen receptor (ER) assay is only performed on one sample. In cases where the assay is performed on more than one sample, there is not necessarily any reason to think that the most accurate is the test done on the "largest" tumor specimen. Clinically, treatment will be based on any positive test; with the benefit and minimal toxicity of hormonal therapy, most patients will be given the "benefit of the doubt" and treated with hormonal therapy if any ER test is positive. Note 3: The most recent interpretation guidelines for ER do not allow for a borderline result. Therefore, code 030 will rarely be used. If 1% or greater cells stain positive, the test results are considered positive. If less than 1% of cells stain positive, the results are considered negative. Code Description 000 010 Positive/elevated 020 Negative/normal; within normal limits 030 Borderline; undetermined whether positive or negative 080 988 996 Test ordered, results not interpretable 997 Test ordered, results not in chart 998 Test not done (test not ordered and not performed) 999 CS Site-Specific Factor 2 Progesterone Receptor (PR) Assay Note 2: In general, progesterone receptor (PR) assay is only performed on one sample. In cases where the assay is performed on more than one sample, there is not necessarily any reason to think that the most accurate is the test done on the "largest" tumor specimen. Clinically, treatment will be based on any positive test; with the benefit and minimal toxicity of hormonal therapy, most patients will be given the "benefit of the doubt" and treated with hormonal therapy if any PR test is positive. Note 3: The most recent interpretation guidelines for PR do not allow for a borderline result. Therefore, code 030 will rarely be used. If 1% or greater cells stain positive, the test results are considered positive. If less than 1% of cells stain positive, the results are considered negative. Code Description 000 010 Positive/elevated 020 Negative/normal; within normal limits 030 Borderline; undetermined whether positive or negative 080 988 996 Test ordered, results not interpretable 997 Test ordered, results not in chart 998 Test not done (test not ordered and not performed) 999 CS Site-Specific Factor 3 Number of Positive Ipsilateral Level I-II Axillary Lymph Nodes Note 1: Include only the number of positive ipsilateral level I and II axillary lymph nodes and intramammary lymph nodes in this field. Intramammary nodes, located within the breast, are not the same as internal mammary nodes, located along the sternum. Note 2: Record this field even if there has been preoperative treatment. Note 3: Lymph nodes with only isolated tumor cells (ITCs) are not counted as positive lymph nodes. Only lymph nodes with metastases greater than 0.2 mm (micrometastases or larger) should be counted as positive. If the pathology report indicates that axillary nodes are positive but size of the metastases is not stated, assume the metastases are greater than 0.2 mm and code the lymph nodes as positive in this field. Note 4: This field is based on pathologic information only. If no ipsilateral axillary nodes are removed for examination, or if an ipsilateral axillary lymph node drainage area is removed but no lymph nodes are found, code 098. Note 5: Instructions in the CSv2 General Rules Part I for Regional Nodes Positive also apply to this field (although the codes in Regional Nodes Positive are 2 digits rather than 3). When positive ipsilateral axillary lymph nodes are coded in this field, the number of positive ipsilateral axillary lymph nodes must be less than or equal to the number coded in Regional Nodes Positive (i.e., the number of positive ipsilateral axillary nodes will always be a subset of the number of positive regional nodes. Code Description 000 All ipsilateral axillary nodes examined negative 001-089 090 90 or more nodes positive 095 Positive aspiration of lymph node(s) 097 Positive nodes, number unspecified 098 No axillary nodes examined 099 988 CS Site-Specific Factor 4 Immunohistochemistry (IHC) of Regional Lymph Nodes Note 1: Isolated tumor cells (ITCs) are defined as single tumor cells or small clusters not greater than 0.2 millimeter (mm), usually detected by immunohistochemistry (IHC), hematoxylin and eosin stains (H and E) (see CS Lymph Nodes code 050), or molecular (MOL) methods (Reverse Transcription Polymerase Chain Reaction, RT-PCR) (see CS Site-Specific Factor 5). ITCs do not usually show evidence of malignant activity (e.g., proliferation or stromal reaction.) Note 2: When CS Lymph Nodes is coded 000, use codes 000-009 only to report results of IHC. Otherwise code 987 in this field. Note 3: If it is unstated whether or not tests are done for IHC, assume they are not done. Note 4: If the record states N0(i+) and no other information, code to 009. Code Description 000 001 Regional lymph nodes negative on routine H and E, IHC studies done, negative for tumor 002 009 888 987 988 CS Site-Specific Factor 5 Molecular (MOL) Studies of Regional Lymph Nodes Note 1: Isolated tumor cells (ITCs) are defined as single tumor cells or small clusters not greater than 0.2 mm, usually detected by immunohistochemistry (IHC) (see CS Site-Specific Factor 4), Hematoxylin and Eosin (H and E) (see CS Lymph Nodes code 050, or molecular (MOL) methods (Reverse Transcription Polymerase Chain Reaction, RT-PCR). ITCs do not usually show evidence of malignant activity (e.g., proliferation or stromal reaction.) Note 2: Use codes 000-002 only to report results of MOL studies (RT-PCR) when CS Lymph Nodes is coded 000. Otherwise code 987 in this field. Note 3: If it is not stated whether molecular tests are done, assume they are not done. Code Description 000 001 002 888 987 988 CS Site-Specific Factor 6 Size of Tumor-Invasive Component Note 1: Record the code that indicates how the pathological tumor size was coded in CS Tumor Size. Note 2: For this field, "mixed" indicates a tumor with both invasive and in situ components. The tumor may be a single histologic type such as mixed infiltrating ductal and ductal carcinoma in situ or a combined histologic type such as mixed infiltrating ductal and lobular carcinoma in situ. "Pure" indicates a tumor that is only invasive or only in situ. Note 3: If size of tumor is given and it is described as an invasive tumor with focal areas of in situ, consider the in situ component to be minimal and use code 030. Code Description 000 010 020 030 040 050 060 888 987 988 CS Site-Specific Factor 7 Nottingham or Bloom-Richardson (BR) Score/Grade Note 1: AJCC recommends the Nottingham combined histologic grade (Elston-Ellis modification of the Scarff-Bloom-Richardson grading system). Terms seen on pathology reports may include: Bloom-Richardson (BR), modified Bloom-Richardson, BR, BR grading, Scarff-Bloom-Richardson, SBR grading, , Elston-Ellis modification of Bloom-Richardson score, Nottingham modification of Bloom-Richardson score, Nottingham modification of Scarff-Bloom-Richardson, Nottingham-Tenovus grade, or Nottingham grade. Note 2: Code the tumor grade using the following priority order: a). BR scores 3-9; b). BR grade (low, intermediate, high). Note 3: BR score may be expressed as a range, 3-9. The score is based on three morphologic features of "invasive no-special-type" breast cancers (degree of tubule formation/histologic grade, mitotic activity, nuclear pleomorphism/nuclear grade of tumor cells). If a report describes any of the factors with words (low, intermediate, high) rather than numbers, do not attempt to translate these words into a score or number; use codes 110-130. Note 4: If only a grade of 1 through 4 is given with no information on the score and it is unclear if it is a Nottingham or BR Grade, code 999. Note 5: Code the highest score if multiple scores are reported. For examples, different scores may be reported on multiple pathology reports for the same primary cancer; different scores may be reported for multiple tumors assigned to the same primary cancer. Code Description 030 Score of 3 040 Score of 4 050 Score of 5 060 Score of 6 070 Score of 7 080 Score of 8 090 Score of 9 110 Low Grade, Bloom-Richardson (BR) grade 1, score not given 120 Medium (Intermediate) Grade, BR grade 2, score not given 130 High Grade, BR grade 3, score not given 988 998 No histologic examination of primary site 999 CS Site-Specific Factor 8 HER2: Immunohistochemistry (IHC) Lab Value Note 1: Record the results of only the immunohistochemistry (IHC) lab value for Human Epidermal Growth Factor Receptor 2 (HER2) in this field. The test determines if there is HER2 overexpression, or an excess amount of HER2 protein on the cell surface. The score is assigned by the pathologist based on the percentage and intensity of cell membrane staining. Note 2: The same laboratory test should be used to record information in CS Site-Specific Factors 8 and 9. Note 3: If the test is done but the actual score is not stated, code 997. Note 4: If the test is not mentioned in the medical record, code to 999 unless there are circumstances under which the test isn't performed, for example no histologic specimen. Code Description 000 Score 0 001 002 003 010 Score of 1+ 020 Score of 2+ 030 Score of 3+ 988 997 Test ordered, results not in chart 998 Test not done (test not ordered and not performed) 999 CS Site-Specific Factor 9 HER2: Immunohistochemistry (IHC) Test Interpretation Note 1: Record the results of only the immunohistochemical (IHC) test for Human Epidermal Growth Factor Receptor 2 (HER2) in this field. Note 2: The same laboratory test should be used to record information in CS Site-Specific Factors 8 and 9. Note 3: If the test is not mentioned in the medical record, code to 999 unless there are circumstances under which the test isn't performed, for example no histologic specimen. Code Description 010 Positive/elevated 020 Negative/normal; within normal limits 030 Borderline; equivocal; indeterminate; undetermined whether positive or negative 988 997 Test ordered, results not in chart 998 Test not done (test not ordered and not performed) 999 CS Site-Specific Factor 10 HER2: Fluorescence In Situ Hybridization (FISH) Lab Value Note 1: Record the results of only the Fluorescence In Situ Hybridization (FISH) test for Human Epidermal Growth Factor Receptor 2 (HER2) in this field. The test determines if there are additional copies of the HER2/neu gene in the tumor cells compared to the normal number. The results are reported as a ratio between the number of copies of the HER2/neu gene and the number of copies of chromosome 17, on which the gene resides. Note 2: Record the actual ratio if given. Enter the stated ratio to two decimal places. Use a trailing zero if needed. Note 3: The same laboratory test should be used to record information in CS Site-Specific Factors 10 and 11. Note 4: If the test is done but the actual ratio is not stated, use code 997. Note 5: If the test is not mentioned in the medical record, code to 999 unless there are circumstances under which the test isn't performed, for example no histologic specimen. Code Description 100-979 980 Ratio of 9.80 or greater 981-986 987 988 991 Ratio of less than 1.00 997 Test ordered, results not in chart 998 Test not done (test not ordered and not performed) 999 CS Site-Specific Factor 11 HER2: Fluorescence In Situ Hybridization (FISH) Test Interpretation Note 1: Record the interpretation of only the Fluorescence In Situ Hybridization (FISH) test for Human Epidermal Growth Factor Receptor 2 (HER2) in this field. Note 2: The same laboratory test should be used to record information in CS Site-Specific Factors 10 and 11. Note 3: If the test is not mentioned in the medical record, code to 999 unless there are circumstances under which the test isn't performed, for example, no histologic specimen. Code Description 010 Positive/elevated; amplified 020 Negative/normal; within normal limits; not amplified 030 Borderline; equivocal; indeterminate; undetermined whether positive or negative 988 997 Test ordered, results not in chart 998 Test not done (test not ordered and not performed) 999 CS Site-Specific Factor 12 HER2: Chromogenic In Situ Hybridization (CISH) Lab Value Note 1: Record the results of only the Chromogenic In Situ Hybridization (CISH) test for Human Epidermal Growth Factor Receptor 2 (HER2) in this field. The test determines whether there are additional copies of the HER2/neu gene in the tumor cells. The results are reported as the mean number of copies of the HER2/neu gene on either 30 or 60 tumor cells. Note 2: Record the actual mean if given. Enter the stated mean to two decimal places. Use a trailing zero if needed. Note 3: The same laboratory test should be used to record information in CS Site-Specific Factors 12 and 13. Note 4: If the test is done but the actual mean is not stated, use code 997. Note 5: If the test is not mentioned in the medical record, code to 999 unless there are circumstances under which the test isn't performed, for example, no histologic specimen. Code Description 100-979 980 Mean of 9.80 or greater 981-986 987 988 991 Mean of less than 1.00 997 Test ordered, results not in chart 998 Test not done (test not ordered and not performed) 999 CS Site-Specific Factor 13 HER2: Chromogenic In Situ Hybridization (CISH) Test Interpretation Note 1: Record the interpretation of only the Chromogenic In Situ Hybridization (CISH) test for Human Epidermal Growth Factor Receptor 2 (HER2) in this field. Note 2: The same laboratory test should be used to record information in CS Site-Specific Factors 12 and 13. Note 3: If the test is not mentioned in the medical record, code to 999 unless there are circumstances under which the test isn't performed, for example, no histologic specimen. Code Description 010 Positive/elevated; amplified 020 Negative/normal; within normal limits; not amplified 030 Borderline; equivocal; indeterminate; undetermined whether positive or negative 988 997 Test ordered, results not in chart 998 Test not done (test not ordered and not performed) 999 CS Site-Specific Factor 14 HER2: Result of Other or Unknown Test Note 1: If another type of in situ hybridization test was performed for Human Epidermal Growth Factor Receptor 2 (HER2), other than fluorescent (FISH) or chromogenic (CISH), record the results here. Note 2: If it is unknown which type of HER2 test was performed, record the results here. Note 3: If no unnamed HER2 test is mentioned in the medical record, code to 999 unless there are circumstances under which the test isn't performed, for example, no histologic specimen. Code Description 010 Positive/elevated; amplified 020 Negative/normal; within normal limits; not amplified 030 Borderline; equivocal; indeterminate; undetermined whether positive or negative 988 997 Test ordered, results not in chart 998 Test not done (test not ordered and not performed) 999 CS Site-Specific Factor 15 HER2: Summary Result of Testing Note 1: The summary of the results of the Immunohistochemistry (IHC), Fluorescent In Situ Hybridization (FISH), Chromogenic In Situ Hybridization (CISH), or other/unknown Human Epidermal Growth Factor Receptor 2 (HER2) test is recorded here. This variable is based on CS Site-Specific Factors 9, 11, 13, and 14. Note 2: If both an IHC and a gene-amplification test (FISH or CISH) are performed, record the result of the gene-amplification test in this field. However, if the gene-amplification test is given first and the result is borderline or equivocal and an IHC test is done to clarify these equivocal results, code the result of the IHC test. Note 3: If the results of one test are available, and it is known that a second test is performed but the results are not available, use code 997. Code Description 010 Positive/elevated; amplified 020 Negative/normal; within normal limits; not amplified 030 Borderline; equivocal; indeterminate; undetermined whether positive or negative 988 997 Test(s) ordered, results not in chart 998 Test(s) not done (test(s) not ordered and not performed) 999 CS Site-Specific Factor 16 Combinations of ER, PR, and HER2 Results Note 1: There is a clinical interest in triple negative breast cancer, or breast cancer that is negative for estrogen receptors (ER), progesterone receptors (PR), and Human Epidermal Growth Factor Receptor 2 (HER2) amplification or overexpression. Note 2: This field is based on CS Site-Specific Factors 1, 2, and 15. Note 3: ER results are coded in the first digit: 0 for negative and 1 for positive. Note 4: PR results are coded in the second digit: 0 for negative and 1 for positive. Note 5: HER2 results are coded in the third digit: 0 for negative and 1 for positive. Note 6: If information is unknown or not available for one or more of the three types of tests, or if one or more of the three types of tests was not performed, code 999. Code Description 000 ER Negative, PR Negative, HER2 Negative (Triple Negative) 001 ER Negative, PR Negative, HER2 Positive 010 ER Negative, PR Positive, HER2 Negative 011 ER Negative, PR Positive, HER2 Positive 100 ER Positive, PR Negative, HER2 Negative 101 ER Positive, PR Negative, HER2 Positive 110 ER Positive, PR Positive, HER2 Negative 111 ER Positive, PR Positive, HER2 Positive 988 999 CS Site-Specific Factor 17 Circulating Tumor Cells (CTC) and Method of Detection Note 1: Circulating tumor cells (CTCs) are isolated tumor cells (ITCs) found in the blood distant from the breast. Note 2: Immunomagnetic separation (IMS) and reverse transcription polymerase chain reaction (RT-PCR) are two components of a laboratory process for identifying very small amounts of tumor cells in tissue. In the IMS process, paramagnetic beads coated with antibodies bind to antigens on tumor cells, which are removed and concentrated by being passed through a magnetic field. RT-PCR is then used to amplify the genetic material to a detectable level. Note 3: Code the results to the test type as expressed in the medical record. Give priority to "IMS" if the report uses both expressions for test type. Code Description 010 Positive, Reverse Transcription Polymerase Chain Reaction (RT-PCR) test 020 Positive, immunomagnetic separation (IMS) test 030 Positive, other test type 040 Positive, unknown test type 110 Negative/normal, RT-PCR test 120 Negative/normal, IMS test 130 Negative/normal, other test type 140 Negative/normal, unknown test type 210 Borderline; equivocal; indeterminate; undetermined if positive or negative, RT-PCR test 220 Borderline; equivocal; indeterminate; undetermined if positive or negative, IMS test 230 Borderline; equivocal; indeterminate; undetermined if positive or negative, other test type 240 Borderline equivocal; indeterminate; undetermined if positive or negative, unknown test type 988 997 Test ordered, results not in chart 998 Test not done (test not ordered and not performed) 999 CS Site-Specific Factor 18 Disseminated Tumor Cells (DTC) and Method of Detection Note 1: Disseminated tumor cells (DTCs) are isolated tumor cells (ITCs) (micrometastases less than or equal to 0.2 mm) found in the bone marrow or other nonregional nodal tissues or organs. Note 2: Immunohistochemistry (IHC) with cytokeratin stains and Reverse Transcription Polymerase Chain Reaction (RT-PCR) are laboratory methods for identifying very small amounts of tumor cells in tissue. RT-PCR amplifies genetic material identified by probes for tumor genes to a detectable level. Note 3: Any positive test takes precedence over a negative or borderline test. Information about a known test takes precedence over no information about other tests. Code Description 010 Positive, Reverse Transcriptase Polymerase Chain Reaction (RT-PCR) test 020 Positive, immunohistochemistry (IHC) test 025 Positive on RT-PCR and IHC 030 Positive, other test type 040 Positive, unknown test type 110 Negative/normal, RT-PCR test 120 Negative/normal IHC test 130 Negative/normal, other test type 140 Negative/normal, unknown test type 210 Borderline; equivocal; indeterminate; undetermined if positive or negative, RT-PCR test 220 Borderline; equivocal; indeterminate; undetermined if positive or negative, IHC test 230 Borderline; equivocal; indeterminate; undetermined if positive or negative, other test type 240 Borderline; equivocal; indeterminate; undetermined if positive or negative, unknown test type 988 997 Test ordered, results not in chart 998 Test not done (test not ordered and not performed) 999 CS Site-Specific Factor 19 Assessment of Positive Ipsilateral Axillary Lymph Nodes Note: Code the assessment method used for the number of positive axillary and intramammary lymph nodes coded in CS Site-Specific Factor 3, Number of Positive Ipsilateral Level I-II Axillary Lymph Nodes. Do not code the assessment method used for Level III axillary nodes or internal mammary nodes. Code Description 000 No ipsilateral axillary lymph nodes positive 010 No nodes examined pathologically: positive nodes on clinical assessment only 015 No nodes examined pathologically: negative nodes on clinical assessment or no clinical assessment 020 Positive fine needle aspiration (FNA) only 025 027 030 Positive core biopsy, incisional only 040 Positive core biopsy, excisional only 050 Positive core biopsy, type not specified only 060 070 100 110 120 123 125 127 130 140 150 Nodes positive, but method of assessment unknown 988 998 999 CS Site-Specific Factor 20 Assessment of Positive Distant Metastases Note 1: Code the assessment method used for determining the presence of metastasis as coded in CS Mets at DX, CS Mets at DX - Bone, CS Mets at DX - Brain, CS Mets at DX - Liver, and CS Mets at DX - Lung. If CS Mets at DX is coded as 00 (no positive metastasis), this field must be coded 000. Note 2: If multiple methods of assessments determined positive metastases, use the highest code that applies. See CSv2 General Rules Part I for types of tests to be included. Code Description 000 No positive metastases identified 005 No clinical or radiographic evidence of distant metastasis, but deposits of molecularly or microscopically detected tumor cells in circulating blood, bone marrow or other non-regional nodal tissue that are 0.2 millimeters (mm) or less in a patient without symptoms or signs of metastasis 010 Physical examination or laboratory tests only 020 030 Incisional biopsy; fine needle aspiration (FNA) 040 Excisional biopsy or resection with microscopic confirmation 988 999 CS Site-Specific Factor 21 Response to Neoadjuvant Therapy Note: Review the medical record for a specific statement by a physician about the response to neoadjuvant therapy. Do not try to interpret or infer a response based on other documentation in the medical record such as a description of residual tumor on the pathology report. Use code 999 if it is unknown if neoadjuvant therapy was given. Code Description 010 Complete response (CR) 020 Partial response (PR) 025 Response noted but no mention if it was complete or partial 030 No response (NR) 987 988 998 999 CS Site-Specific Factor 22 Multigene Signature Method Note 1: Multigene signatures or classifiers are assays of a panel of genes from a tumor specimen, intended to provide a quantitative assessment of the likelihood of response to chemotherapy and to evaluate prognosis or distant recurrence. Oncotype DX and MammaPrint (also called MammoPrint) are two commercially available genomic tests. Note 2: Code the type of test performed. The same test should be used to record information in CS Site-Specific Factors 22 and 23. Note 3: This information may not be available at diagnosis and may require follow-up with the physician. Code Description 010 Oncotype DX 020 MammaPrint (MammoPrint) 030 Other 040 Test performed, type of test unknown 988 997 998 Test not done (test not ordered and not performed) 999 CS Site-Specific Factor 23 Multigene Signature Results Note 1: The results for the Oncotype DX test are expressed as a percentage Recurrence Score ranging from 0 to 100, with risk assessment in the categories of low, intermediate, and high. Note 2: The results for the MammaPrint test are expressed as low risk for distant recurrence and high risk for distant recurrence. Note 3: Code the score or results of the multigene signature assay recorded in CS Site-Specific Factor 22. Code the percentage score for Oncotype DX if available in preference to the risk assessment. Code the risk assessment for MammaPrint. Note 4: This information may not be available at diagnosis and may require follow-up with the physician. Code Description 000-100 200 Low risk of recurrence (good prognosis) 205 300 Intermediate risk of recurrence 400 High risk of recurrence (poor prognosis) 988 997 Test ordered, results not in chart 998 Test not done (test not ordered and not performed) 999 CS Site-Specific Factor 24 Paget Disease Note 1: Record any mention of Paget disease, whether clinical or pathologic, giving priority to the pathologic assessment. Information may be taken from the gross or microscopic section of the pathology report. Interpret a negative exam of the nipple as Paget disease not present. Note 2: Use code 020 when pathology report states pagetoid involvement of the nipple. Do not use code 020 if report states pagetoid involvement of ducts or lobules. Note 3: Use code 999 (Unknown) when no examination of the nipple, clinical or pathologic, is available in the medical record. Code Description 000 Paget disease absent 010 Paget disease present 020 Stated as pagetoid involvement of nipple 988 999 ¬appnewssf25; &commonhistinclusioncarcinomaplusphyllodes; Histology Exclusion Table AJCC 6th ed. Note: Histology codes listed in this Histology Exclusion Table for this site are codes that are not TNM staged according to the AJCC 6th Edition Cancer Staging Manual. When a case is coded in Collaborative Staging and the histology is on the exclusion list, TNM will not be calculated but SEER algorithm Summary Stage 1977 and 2000 can be assigned. For these cases, displayed results will be "T NA N NA M NA and Stage Group NA". Code Description 8240/1 Carcinoid tumor of uncertain malignant potential 8240/3 Carcinoid tumor, NOS (except of appendix M-8240/1) 8241/3 Enterochromaffin cell carcinoid 8242/1 Enterochromaffin-like cell carcinoid, NOS 8242/3 Enterochromaffin-like cell tumor, malignant 8243/3 Goblet cell carcinoid 8248/1 Apudoma 8249/3 Atypical carcinoid tumor 8680/0 Paraganglioma, benign 8680/1 Paraganglioma, NOS 8680/3 Paraganglioma, malignant 8681/1 Sympathetic paraganglioma 8682/1 Parasympathetic paraganglioma 8683/0 Gangliocytic paraganglioma (C17.0) 8690/1 Glomus jugulare tumor, NOS (C75.5) 8691/1 Aortic body tumor (C75.5) 8692/1 Carotid body tumor (C75.4) 8693/1 Extra-adrenal paraganglioma, NOS 8693/3 Extra-adrenal paraganglioma, malignant 8700/0 Pheochromocytoma, NOS (C74.1) 8700/3 Pheochromocytoma, malignant (C74.1) 8710/3 Glomangiosarcoma 8711/0 Glomus tumor, NOS 8711/3 Glomus tumor, malignant 8712/0 Glomangioma 8713/0 Glomangiomyoma 8720/0 Pigmented nevus, NOS (C44._) 8720/2 Melanoma in situ 8720/3 Malignant melanoma, NOS (except juvenile melanoma M-8770/0) 8721/3 Nodular melanoma (C44._) 8722/0 Balloon cell nevus (C44._) 8722/3 Balloon cell melanoma (C44._) 8723/0 Halo nevus (C44._) 8723/3 Malignant melanoma, regressing (C44._) 8725/0 Neuronevus (C44._) 8726/0 Magnocellular nevus (C69.4) 8727/0 Dysplastic nevus (C44._) 8728/0 Diffuse melanocytosis (C70.9) 8728/1 Meningeal melanocytoma (C70.9) 8728/3 Meningeal melanomatosis (C70.9) 8730/0 Nonpigmented nevus (C44._) 8730/3 Amelanotic melanoma (C44._) 8740/0 Junctional nevus, NOS (C44._) 8740/3 Malignant melanoma in junctional nevus (C44._) 8741/2 Precancerous melanosis, NOS (C44._) 8741/3 Malignant melanoma in precancerous melanosis (C44._) 8742/2 Lentigo maligna (C44._) 8742/3 Lentigo maligna melanoma (C44._) 8743/3 Superficial spreading melanoma (C44._) 8744/3 Acral lentiginous melanoma, malignant (C44._) 8745/3 Desmoplastic melanoma, malignant (C44._) 8746/3 Mucosal lentiginous melanoma 8750/0 Intradermal nevus (C44._) 8760/0 Compound nevus (C44._) 8761/0 Small congenital nevus (C44._) 8761/1 Giant pigmented nevus, NOS (C44._) 8761/3 Malignant melanoma in giant pigmented nevus (C44._) 8762/1 Proliferative dermal lesion in congenital nevus (C44._) 8770/0 Epithelioid and spindle cell nevus (C44._) 8770/3 Mixed epithelioid and spindle cell melanoma 8771/0 Epithelioid cell nevus (C44._) 8771/3 Epithelioid cell melanoma 8772/0 Spindle cell nevus, NOS (C44._) 8772/3 Spindle cell melanoma, NOS 8773/3 Spindle cell melanoma, type A (C69._) 8774/3 Spindle cell melanoma, type B (C69._) 8780/0 Blue nevus, NOS (C44._) 8780/3 Blue nevus, malignant (C44._) 8790/0 Cellular blue nevus (C44._) 8800/0 Soft tissue tumor, benign 8800/3 Sarcoma, NOS 8800/9 Sarcomatosis, NOS 8801/3 Spindle cell sarcoma 8802/3 Giant cell sarcoma (except of bone M-9250/3) 8803/3 Small cell sarcoma 8804/3 Epithelioid sarcoma 8805/3 Undifferentiated sarcoma 8806/3 Desmoplastic small round cell tumor 8810/0 Fibroma, NOS 8810/1 Cellular fibroma (C56.9) 8810/3 Fibrosarcoma, NOS 8811/0 Fibromyxoma 8811/3 Fibromyxosarcoma 8812/0 Periosteal fibroma (C40._, C41._) 8812/3 Periosteal fibrosarcoma (C40._, C41._) 8813/0 Fascial fibroma 8813/3 Fascial fibrosarcoma 8814/3 Infantile fibrosarcoma 8815/0 Solitary fibrous tumor 8815/3 Solitary fibrous tumor, malignant 8820/0 Elastofibroma 8821/1 Aggressive fibromatosis 8822/1 Abdominal fibromatosis 8823/0 Desmoplastic fibroma 8824/0 Myofibroma 8824/1 Myofibromatosis 8825/0 Myofibroblastoma 8825/1 Myofibroblastic tumor, NOS 8826/0 Angiomyofibroblastoma 8827/1 Myofibroblastic tumor, peribronchial (C34._) 8830/0 Benign fibrous histiocytoma 8830/1 Atypical fibrous histiocytoma 8830/3 Malignant fibrous histiocytoma 8831/0 Histiocytoma, NOS 8832/0 Dermatofibroma, NOS (C44._) 8832/3 Dermatofibrosarcoma, NOS (C44._) 8833/3 Pigmented dermatofibrosarcoma protuberans (C44._) 8834/1 Giant cell fibroblastoma 8835/1 Plexiform fibrohistiocytic tumor 8836/1 Angiomatoid fibrous histiocytoma 8840/0 Myxoma, NOS 8840/3 Myxosarcoma 8841/1 Angiomyxoma 8842/0 Ossifying fibromyxoid tumor 8850/0 Lipoma, NOS 8850/1 Atypical lipoma 8850/3 Liposarcoma, NOS 8851/0 Fibrolipoma 8851/3 Liposarcoma, well differentiated 8852/0 Fibromyxolipoma 8852/3 Myxoid liposarcoma 8853/3 Round cell liposarcoma 8854/0 Pleomorphic lipoma 8854/3 Pleomorphic liposarcoma 8855/3 Mixed liposarcoma 8856/0 Intramuscular lipoma 8857/0 Spindle cell lipoma 8857/3 Fibroblastic liposarcoma 8858/3 Dedifferentiated liposarcoma 8860/0 Angiomyolipoma 8861/0 Angiolipoma, NOS 8862/0 Chondroid lipoma 8870/0 Myelolipoma 8880/0 Hibernoma 8881/0 Lipoblastomatosis 8890/0 Leiomyoma, NOS 8890/1 Leiomyomatosis, NOS 8890/3 Leiomyosarcoma, NOS 8891/0 Epithelioid leiomyoma 8891/3 Epithelioid leiomyosarcoma 8892/0 Cellular leiomyoma 8893/0 Bizarre leiomyoma 8894/0 Angiomyoma 8894/3 Angiomyosarcoma 8895/0 Myoma 8895/3 Myosarcoma 8896/3 Myxoid leiomyosarcoma 8897/1 Smooth muscle tumor of uncertain malignant potential 8898/1 Metastasizing leiomyoma 8900/0 Rhabdomyoma, NOS 8900/3 Rhabdomyosarcoma, NOS 8901/3 Pleomorphic rhabdomyosarcoma, adult type 8902/3 Mixed type rhabdomyosarcoma 8903/0 Fetal rhabdomyoma 8904/0 Adult rhabdomyoma 8905/0 Genital rhabdomyoma (C51._, C52.9) 8910/3 Embryonal rhabdomyosarcoma, NOS 8912/3 Spindle cell rhabdomyosarcoma 8920/3 Alveolar rhabdomyosarcoma 8921/3 Rhabdomyosarcoma with ganglionic differentiation 8930/0 Endometrial stromal nodule (C54.1) 8930/3 Endometrial stromal sarcoma, NOS (C54.1) 8931/3 Endometrial stromal sarcoma, low grade (C54.1) 8932/0 Adenomyoma 8933/3 Adenosarcoma 8934/3 Carcinofibroma 8935/0 Stromal tumor, benign 8935/1 Stromal tumor, NOS 8935/3 Stromal sarcoma, NOS 8936/0 Gastrointestinal stromal tumor, benign 8936/1 Gastrointestinal stromal tumor, NOS 8936/3 Gastrointestinal stromal sarcoma 8950/3 Mullerian mixed tumor (C54._) 8951/3 Mesodermal mixed tumor 8959/0 Benign cystic nephroma (C64.9) 8959/1 Cystic partially differentiated nephroblastoma (C64.9) 8959/3 Malignant cystic nephroma (C64.9) 8960/1 Mesoblastic nephroma 8960/3 Nephroblastoma, NOS (C64.9) 8963/3 Malignant rhabdoid tumor 8964/3 Clear cell sarcoma of kidney (C64.9) 8965/0 Nephrogenic adenofibroma (C64.9) 8966/0 Renomedullary interstitial cell tumor (C64.9) 8967/0 Ossifying renal tumor (C64.9) 8970/3 Hepatoblastoma (C22.0) 8971/3 Pancreatoblastoma (C25._) 8972/3 Pulmonary blastoma (C34._) 8973/3 Pleuropulmonary blastoma 8974/1 Sialoblastoma 8980/3 Carcinosarcoma, NOS 8981/3 Carcinosarcoma, embryonal 8983/0 Adenomyoepithelioma (C50._) 8990/0 Mesenchymoma, benign 8990/1 Mesenchymoma, NOS 8990/3 Mesenchymoma, malignant 8991/3 Embryonal sarcoma 9000/0 Brenner tumor, NOS (C56.9) 9000/1 Brenner tumor, borderline malignancy (C56.9) 9000/3 Brenner tumor, malignant (C56.9) 9010/0 Fibroadenoma, NOS (C50._) 9011/0 Intracanalicular fibroadenoma (C50._) 9012/0 Pericanalicular fibroadenoma (C50._) 9013/0 Adenofibroma, NOS 9014/0 Serous adenofibroma, NOS 9014/1 Serous adenofibroma of borderline malignancy 9014/3 Serous adenocarcinofibroma 9015/0 Mucinous adenofibroma, NOS 9015/1 Mucinous adenofibroma of borderline malignancy 9015/3 Mucinous adenocarcinofibroma 9016/0 Giant fibroadenoma (C50._) 9030/0 Juvenile fibroadenoma (C50._) 9040/0 Synovioma, benign 9040/3 Synovial sarcoma, NOS 9041/3 Synovial sarcoma, spindle cell 9042/3 Synovial sarcoma, epithelioid cell 9043/3 Synovial sarcoma, biphasic 9044/3 Clear cell sarcoma, NOS (except of kidney M-8964/3) 9050/0 Mesothelioma, benign 9050/3 Mesothelioma, malignant 9051/0 Fibrous mesothelioma, benign 9051/3 Fibrous mesothelioma, malignant 9052/0 Epithelioid mesothelioma, benign 9052/3 Epithelioid mesothelioma, malignant 9053/3 Mesothelioma, biphasic, malignant 9054/0 Adenomatoid tumor, NOS 9055/0 Multicystic mesothelioma, benign 9055/1 Cystic mesothelioma, NOS (C48._) 9060/3 Dysgerminoma 9061/3 Seminoma, NOS (C62._) 9062/3 Seminoma, anaplastic (C62._) 9063/3 Spermatocytic seminoma (C62._) 9064/2 Intratubular malignant germ cells (C62._) 9064/3 Germinoma 9065/3 Germ cell tumor, nonseminomatous (C62._) 9070/3 Embryonal carcinoma, NOS 9071/3 Yolk sac tumor 9072/3 Polyembryoma 9073/1 Gonadoblastoma 9080/0 Teratoma, benign 9080/1 Teratoma, NOS 9080/3 Teratoma, malignant, NOS 9081/3 Teratocarcinoma 9082/3 Malignant teratoma, undifferentiated 9083/3 Malignant teratoma, intermediate 9084/0 Dermoid cyst, NOS 9084/3 Teratoma with malignant transformation 9085/3 Mixed germ cell tumor 9090/0 Struma ovarii, NOS (C56.9) 9090/3 Struma ovarii, malignant (C56.9) 9091/1 Strumal carcinoid (C56.9) 9100/0 Hydatidiform mole, NOS (C58.9) 9100/1 Invasive hydatidiform mole (C58.9) 9100/3 Choriocarcinoma, NOS 9101/3 Choriocarcinoma combined with other germ cell elements 9102/3 Malignant teratoma, trophoblastic 9103/0 Partial hydatidiform mole (C58.9) 9104/1 Placental site trophoblastic tumor (C58.9) 9105/3 Trophoblastic tumor, epithelioid 9110/0 Mesonephroma, benign 9110/1 Mesonephric tumor, NOS 9110/3 Mesonephroma, malignant 9120/0 Hemangioma, NOS 9120/3 Hemangiosarcoma 9121/0 Cavernous hemangioma 9122/0 Venous hemangioma 9123/0 Racemose hemangioma 9124/3 Kupffer cell sarcoma (C22.0) 9125/0 Epithelioid hemangioma 9130/0 Hemangioendothelioma, benign 9130/1 Hemangioendothelioma, NOS 9130/3 Hemangioendothelioma, malignant 9131/0 Capillary hemangioma 9132/0 Intramuscular hemangioma 9133/1 Epithelioid hemangioendothelioma, NOS 9133/3 Epithelioid hemangioendothelioma, malignant 9135/1 Endovascular papillary angioendothelioma 9136/1 Spindle cell hemangioendothelioma 9140/3 Kaposi sarcoma 9141/0 Angiokeratoma 9142/0 Verrucous keratotic hemangioma 9150/0 Hemangiopericytoma, benign 9150/1 Hemangiopericytoma, NOS 9150/3 Hemangiopericytoma, malignant 9160/0 Angiofibroma, NOS 9161/0 Acquired tufted hemangioma 9161/1 Hemangioblastoma 9170/0 Lymphangioma, NOS 9170/3 Lymphangiosarcoma 9171/0 Capillary lymphangioma 9172/0 Cavernous lymphangioma 9173/0 Cystic lymphangioma 9174/0 Lymphangiomyoma 9174/1 Lymphangiomyomatosis 9175/0 Hemolymphangioma 9180/0 Osteoma, NOS (C40._, C41._) 9180/3 Osteosarcoma, NOS (C40._, C41._) 9181/3 Chondroblastic osteosarcoma (C40._, C41._) 9182/3 Fibroblastic osteosarcoma (C40._, C41._) 9183/3 Telangiectatic osteosarcoma (C40._, C41._) 9184/3 Osteosarcoma in Paget disease of bone (C40._, C41._) 9185/3 Small cell osteosarcoma (C40._, C41._) 9186/3 Central osteosarcoma (C40._, C41._) 9187/3 Intraosseous well differentiated osteosarcoma (C40._, C41._) 9191/0 Osteoid osteoma, NOS (C40._, C41._) 9192/3 Parosteal osteosarcoma (C40._, C41._) 9193/3 Periosteal osteosarcoma (C40._, C41._) 9194/3 High grade surface osteosarcoma (C40._, C41._) 9195/3 Intracortical osteosarcoma (C40._, C41._) 9200/0 Osteoblastoma, NOS (C40._, C41._) 9200/1 Aggressive osteoblastoma (C40._, C41._) 9210/0 Osteochondroma (C40._, C41._) 9210/1 Osteochondromatosis, NOS (C40._, C41._) 9220/0 Chondroma, NOS (C40._, C41._) 9220/1 Chondromatosis, NOS 9220/3 Chondrosarcoma, NOS (C40._, C41._) 9221/0 Juxtacortical chondroma (C40._, C41._) 9221/3 Juxtacortical chondrosarcoma (C40._, C41._) 9230/0 Chondroblastoma, NOS (C40._, C41._) 9230/3 Chondroblastoma, malignant (C40._, C41._) 9231/3 Myxoid chondrosarcoma 9240/3 Mesenchymal chondrosarcoma 9241/0 Chondromyxoid fibroma (C40._, C41._) 9242/3 Clear cell chondrosarcoma (C40._, C41._) 9243/3 Dedifferentiated chondrosarcoma (C40._, C41._) 9250/1 Giant cell tumor of bone, NOS (C40._, C41._) 9250/3 Giant cell tumor of bone, malignant (C40._, C41._) 9251/1 Giant cell tumor of soft parts, NOS 9251/3 Malignant giant cell tumor of soft parts 9252/0 Tenosynovial giant cell tumor (C49._) 9252/3 Malignant tenosynovial giant cell tumor (C49._) 9260/3 Ewing sarcoma 9261/3 Adamantinoma of long bones (C40._) 9262/0 Ossifying fibroma 9270/0 Odontogenic tumor, benign 9270/1 Odontogenic tumor, NOS 9270/3 Odontogenic tumor, malignant 9271/0 Ameloblastic fibrodentinoma 9272/0 Cementoma, NOS 9273/0 Cementoblastoma, benign 9274/0 Cementifying fibroma 9275/0 Gigantiform cementoma 9280/0 Odontoma, NOS 9281/0 Compound odontoma 9282/0 Complex odontoma 9290/0 Ameloblastic fibro-odontoma 9290/3 Ameloblastic odontosarcoma 9300/0 Adenomatoid odontogenic tumor 9301/0 Calcifying odontogenic cyst 9302/0 Odontogenic ghost cell tumor 9310/0 Ameloblastoma, NOS 9310/3 Ameloblastoma, malignant 9311/0 Odontoameloblastoma 9312/0 Squamous odontogenic tumor 9320/0 Odontogenic myxoma 9321/0 Central odontogenic fibroma 9322/0 Peripheral odontogenic fibroma 9330/0 Ameloblastic fibroma 9330/3 Ameloblastic fibrosarcoma 9340/0 Calcifying epithelial odontogenic tumor 9341/1 Clear cell odontogenic tumor 9342/3 Odontogenic carcinosarcoma 9350/1 Craniopharyngioma (C75.2) 9351/1 Craniopharyngioma, adamantinomatous (C75.2) 9352/1 Craniopharyngioma, papillary (C75.2) 9360/1 Pinealoma (C75.3) 9361/1 Pineocytoma (C75.3) 9362/3 Pineoblastoma (C75.3) 9363/0 Melanotic neuroectodermal tumor 9364/3 Peripheral neuroectodermal tumor 9365/3 Askin tumor 9370/3 Chordoma, NOS 9371/3 Chondroid chordoma 9372/3 Dedifferentiated chordoma 9373/0 Parachordoma 9380/3 Glioma, malignant (C71._) 9381/3 Gliomatosis cerebri (C71._) 9382/3 Mixed glioma (C71._) 9383/1 Subependymoma (C71._) 9384/1 Subependymal giant cell astrocytoma (C71._) 9390/0 Choroid plexus papilloma, NOS (C71.5) 9390/1 Atypical choroid plexus papilloma (C71.5) 9390/3 Choroid plexus carcinoma (C71.5) 9391/3 Ependymoma, NOS (C71._) 9392/3 Ependymoma, anaplastic (C71._) 9393/3 Papillary ependymoma (C71._) 9394/1 Myxopapillary ependymoma (C72.0) 9400/3 Astrocytoma, NOS (C71._) 9401/3 Astrocytoma, anaplastic (C71._) 9410/3 Protoplasmic astrocytoma (C71._) 9411/3 Gemistocytic astrocytoma (C71._) 9412/1 Desmoplastic infantile astrocytoma (C71._) 9413/0 Dysembryoplastic neuroepithelial tumor 9420/3 Fibrillary astrocytoma (C71._) 9421/1 Pilocytic astrocytoma (C71._) 9423/3 Polar spongioblastoma (C71._) 9424/3 Pleomorphic xanthoastrocytoma (C71._) 9430/3 Astroblastoma (C71._) 9440/3 Glioblastoma, NOS (C71._) 9441/3 Giant cell glioblastoma (C71._) 9442/1 Gliofibroma (C71._) 9442/3 Gliosarcoma (C71._) 9444/1 Chordoid glioma (C71._) 9450/3 Oligodendroglioma, NOS (C71._) 9451/3 Oligodendroglioma, anaplastic (C71._) 9460/3 Oligodendroblastoma (C71._) [obs] 9470/3 Medulloblastoma, NOS (C71.6) 9471/3 Desmoplastic nodular medulloblastoma (C71.6) 9472/3 Medullomyoblastoma (C71.6) 9473/3 Primitive neuroectodermal tumor, NOS 9474/3 Large cell medulloblastoma (C71.6) 9480/3 Cerebellar sarcoma, NOS (C71.6) [obs] 9490/0 Ganglioneuroma 9490/3 Ganglioneuroblastoma 9491/0 Ganglioneuromatosis 9492/0 Gangliocytoma 9493/0 Dysplastic gangliocytoma of cerebellum (Lhermitte-Duclos) (C71.6) 9500/3 Neuroblastoma, NOS 9501/0 Medulloepithelioma, benign (C69.4) 9501/3 Medulloepithelioma, NOS 9502/0 Teratoid medulloepithelioma, benign (C69.4) 9502/3 Teratoid medulloepithelioma 9503/3 Neuroepithelioma, NOS 9504/3 Spongioneuroblastoma 9505/1 Ganglioglioma, NOS 9505/3 Ganglioglioma, anaplastic 9506/1 Central neurocytoma 9507/0 Pacinian tumor 9508/3 Atypical teratoid/rhabdoid tumor (C71._) 9510/0 Retinocytoma (C69.2) 9510/3 Retinoblastoma, NOS (C69.2) 9511/3 Retinoblastoma, differentiated (C69.2) 9512/3 Retinoblastoma, undifferentiated (C69.2) 9513/3 Retinoblastoma, diffuse (C69.2) 9514/1 Retinoblastoma, spontaneously regressed (C69.2) 9520/3 Olfactory neurogenic tumor 9521/3 Olfactory neurocytoma (C30.0) 9522/3 Olfactory neuroblastoma (C30.0) 9523/3 Olfactory neuroepithelioma (C30.0) 9530/0 Meningioma, NOS 9530/1 Meningiomatosis, NOS 9530/3 Meningioma, malignant 9531/0 Meningothelial meningioma 9532/0 Fibrous meningioma 9533/0 Psammomatous meningioma 9534/0 Angiomatous meningioma 9535/0 Hemangioblastic meningioma [obs] 9537/0 Transitional meningioma 9538/1 Clear cell meningioma 9538/3 Papillary meningioma 9539/1 Atypical meningioma 9539/3 Meningeal sarcomatosis 9540/0 Neurofibroma, NOS 9540/1 Neurofibromatosis, NOS 9540/3 Malignant peripheral nerve sheath tumor 9541/0 Melanotic neurofibroma 9550/0 Plexiform neurofibroma 9560/0 Neurilemoma, NOS 9560/1 Neurinomatosis 9560/3 Neurilemoma, malignant [obs] 9561/3 Malignant peripheral nerve sheath tumor with rhabdomyoblastic differentiation 9562/0 Neurothekeoma 9570/0 Neuroma, NOS 9571/0 Perineurioma, NOS 9571/3 Perineurioma, malignant 9580/0 Granular cell tumor, NOS 9580/3 Granular cell tumor, malignant 9581/3 Alveolar soft part sarcoma 9582/0 Granular cell tumor of the sellar region (C75.1) 9590/3 Malignant lymphoma, NOS 9591/3 Malignant lymphoma, non-Hodgkin, NOS 9596/3 Composite Hodgkin and non-Hodgkin lymphoma 9650/3 Hodgkin lymphoma, NOS 9651/3 Hodgkin lymphoma, lymphocyte-rich 9652/3 Hodgkin lymphoma, mixed cellularity, NOS 9653/3 Hodgkin lymphoma, lymphocyte depletion, NOS 9654/3 Hodgkin lymphoma, lymphocyte depletion, diffuse fibrosis 9655/3 Hodgkin lymphoma, lymphocyte depletion, reticular 9659/3 Hodgkin lymphoma, nodular lymphocyte predominance 9661/3 Hodgkin granuloma [obs] 9662/3 Hodgkin sarcoma [obs] 9663/3 Hodgkin lymphoma, nodular sclerosis, NOS 9664/3 Hodgkin lymphoma, nodular sclerosis, cellular phase 9665/3 Hodgkin lymphoma, nodular sclerosis, grade 1 9667/3 Hodgkin lymphoma, nodular sclerosis, grade 2 9670/3 Malignant lymphoma, small B lymphocytic, NOS (see also M-9823/3) 9671/3 Malignant lymphoma, lymphoplasmacytic (see also M-9761/3) 9673/3 Mantle cell lymphoma 9675/3 Malignant lymphoma, mixed small and large cell, diffuse [obs] (see also M-9690/3) 9678/3 Primary effusion lymphoma 9679/3 Mediastinal large B-cell lymphoma (C38.3) 9680/3 Malignant lymphoma, large B-cell, diffuse, NOS 9684/3 Malignant lymphoma, large B-cell, diffuse, immunoblastic, NOS 9687/3 Burkitt lymphoma, NOS (see also M-9826/3) 9689/3 Splenic marginal zone B-cell lymphoma (C42.2) 9690/3 Follicular lymphoma, NOS (see also M-9675/3) 9691/3 Follicular lymphoma, grade 2 9695/3 Follicular lymphoma, grade 1 9698/3 Follicular lymphoma, grade 3 9699/3 Marginal zone B-cell lymphoma, NOS 9700/3 Mycosis fungoides (C44._) 9701/3 Sezary syndrome 9702/3 Mature T-cell lymphoma, NOS 9705/3 Angioimmunoblastic T-cell lymphoma 9708/3 Subcutaneous panniculitis-like T-cell lymphoma 9709/3 Cutaneous T-cell lymphoma, NOS (C44._) 9714/3 Anaplastic large cell lymphoma, T cell and Null cell type 9716/3 Hepatosplenic ?? (gamma-delta) cell lymphoma 9717/3 Intestinal T-cell lymphoma 9718/3 Primary cutaneous CD30+ T-cell lymphoproliferative disorder (C44._) 9719/3 NK/T-cell lymphoma, nasal and nasal-type 9727/3 Precursor cell lymphoblastic lymphoma, NOS (see also M-9835/3) 9728/3 Precursor B-cell lymphoblastic lymphoma (see also M-9836/3) 9729/3 Precursor T-cell lymphoblastic lymphoma (see also M-9837/3) 9731/3 Plasmacytoma, NOS 9732/3 Multiple myeloma (C42.1) 9733/3 Plasma cell leukemia (C42.1) 9734/3 Plasmacytoma, extramedullary (not occurring in bone) 9740/1 Mastocytoma, NOS 9740/3 Mast cell sarcoma 9741/3 Malignant mastocytosis 9742/3 Mast cell leukemia (C42.1) 9750/3 Malignant histiocytosis 9751/1 Langerhans cell histiocytosis, NOS 9752/1 Langerhans cell histiocytosis, unifocal 9753/1 Langerhans cell histiocytosis, multifocal 9754/3 Langerhans cell histiocytosis, disseminated 9755/3 Histiocytic sarcoma 9756/3 Langerhans cell sarcoma 9757/3 Interdigitating dendritic cell sarcoma 9758/3 Follicular dendritic cell sarcoma 9760/3 Immunoproliferative disease, NOS 9761/3 Waldenstrom macroglobulinemia (C42.0) (see also M-9671/3) 9762/3 Heavy chain disease, NOS 9764/3 Immunoproliferative small intestinal disease (C17._) 9765/1 Monoclonal gammopathy of undetermined significance 9766/1 Angiocentric immunoproliferative lesion 9767/1 Angioimmunoblastic lymphadenopathy 9768/1 T-gamma lymphoproliferative disease 9769/1 Immunoglobulin deposition disease 9800/3 Leukemia, NOS 9801/3 Acute leukemia, NOS 9805/3 Acute biphenotypic leukemia 9820/3 Lymphoid leukemia, NOS 9823/3 B-cell chronic lymphocytic leukemia/small lymphocytic lymphoma (see also M-9670/3) 9826/3 Burkitt cell leukemia (see also M-9687/3) 9827/3 Adult T-cell leukemia/lymphoma (HTLV-1 positive) Includes all variants 9831/1 T-cell large granular lymphocytic leukemia 9832/3 Prolymphocytic leukemia, NOS 9833/3 Prolymphocytic leukemia, B-cell type 9834/3 Prolymphocytic leukemia, T-cell type 9835/3 Precursor cell lymphoblastic leukemia, NOS (see also M-9727/3) 9836/3 Precursor B-cell lymphoblastic leukemia (see also M-9728/3) 9837/3 Precursor T-cell lymphoblastic leukemia (see also M-9729/3) 9840/3 Acute myeloid leukemia, M6 type 9860/3 Myeloid leukemia, NOS 9861/3 Acute myeloid leukemia, NOS (FAB or WHO type not specified) (see also M-9930/3) 9863/3 Chronic myeloid leukemia, NOS 9866/3 Acute promyelocytic leukemia, t(15;17)(q22;q11-12) 9867/3 Acute myelomonocytic leukemia 9870/3 Acute basophilic leukemia 9871/3 Acute myeloid leukemia with abnormal marrow eosinophils Includes all variants 9872/3 Acute myeloid leukemia, minimal differentiation 9873/3 Acute myeloid leukemia without maturation 9874/3 Acute myeloid leukemia with maturation 9875/3 Chronic myelogenous leukemia, BCR/ABL positive 9876/3 Atypical chronic myeloid leukemia, BCR/ABL negative 9891/3 Acute monocytic leukemia 9895/3 Acute myeloid leukemia with multilineage dysplasia 9896/3 Acute myeloid leukemia, t(8;21)(q22;q22) 9897/3 Acute myeloid leukemia, 11q23 abnormalities 9910/3 Acute megakaryoblastic leukemia 9920/3 Therapy-related acute myeloid leukemia, NOS 9930/3 Myeloid sarcoma (see also M-9861/3) 9931/3 Acute panmyelosis with myelofibrosis (C42.1) 9940/3 Hairy cell leukemia (C42.1) 9945/3 Chronic myelomonocytic leukemia, NOS 9946/3 Juvenile myelomonocytic leukemia 9948/3 Aggressive NK-cell leukemia 9950/3 Polycythemia vera 9960/3 Chronic myeloproliferative disease, NOS 9961/3 Myelosclerosis with myeloid metaplasia 9962/3 Essential thrombocythemia 9963/3 Chronic neutrophilic leukemia 9964/3 Hypereosinophilic syndrome 9970/1 Lymphoproliferative disorder, NOS 9975/1 Myeloproliferative disease, NOS 9980/3 Refractory anemia 9982/3 Refractory anemia with sideroblasts 9983/3 Refractory anemia with excess blasts 9984/3 Refractory anemia with excess blasts in transformation [obs] 9985/3 Refractory cytopenia with multilineage dysplasia 9986/3 Myelodysplastic syndrome with 5q deletion (5q-) syndrome 9987/3 Therapy-related myelodysplastic syndrome, NOS 9989/3 Myelodysplastic syndrome, NOS AJCC TNM 7 Stage T N M Stage T0 N0 M0 ERROR T0 N0(i-) M0 ERROR T0 N0(i+) M0 ERROR T0 N0(mol-) M0 ERROR T0 N0(mol+) M0 ERROR T0 N1 M0 IIA T0 N1a M0 IIA T0 N1b M0 IIA T0 N1c M0 IIA T0 N1mi M0 IB T0 N1NOS M0 IIA T0 N2a M0 IIIA T0 N2b M0 IIIA T0 N2NOS M0 IIIA T0 N3a M0 IIIC T0 N3b M0 IIIC T0 N3c M0 IIIC T0 N3NOS M0 IIIC T0 NX M0 UNK Tis N0 M0 0 Tis N0(i-) M0 0 Tis N0(i+) M0 0 Tis N0(mol-) M0 0 Tis N0(mol+) M0 0 Tis N1 M0 ERROR Tis N1a M0 ERROR Tis N1b M0 ERROR Tis N1c M0 ERROR Tis N1mi M0 ERROR Tis N1NOS M0 ERROR Tis N2a M0 ERROR Tis N2b M0 ERROR Tis N2NOS M0 ERROR Tis N3a M0 ERROR Tis N3b M0 ERROR Tis N3c M0 ERROR Tis N3NOS M0 ERROR Tis NX M0 0 T1mi N0 M0 IA T1mi N0(i-) M0 IA T1mi N0(i+) M0 IA T1mi N0(mol-) M0 IA T1mi N0(mol+) M0 IA T1mi N1 M0 IIA T1mi N1a M0 IIA T1mi N1b M0 IIA T1mi N1c M0 IIA T1mi N1mi M0 IB T1mi N1NOS M0 IIA T1mi N2a M0 IIIA T1mi N2b M0 IIIA T1mi N2NOS M0 IIIA T1mi N3a M0 IIIC T1mi N3b M0 IIIC T1mi N3c M0 IIIC T1mi N3NOS M0 IIIC T1mi NX M0 UNK T1a N0 M0 IA T1a N0(i-) M0 IA T1a N0(i+) M0 IA T1a N0(mol-) M0 IA T1a N0(mol+) M0 IA T1a N1 M0 IIA T1a N1a M0 IIA T1a N1b M0 IIA T1a N1c M0 IIA T1a N1mi M0 IB T1a N1NOS M0 IIA T1a N2a M0 IIIA T1a N2b M0 IIIA T1a N2NOS M0 IIIA T1a N3a M0 IIIC T1a N3b M0 IIIC T1a N3c M0 IIIC T1a N3NOS M0 IIIC T1a NX M0 UNK T1b N0 M0 IA T1b N0(i-) M0 IA T1b N0(i+) M0 IA T1b N0(mol-) M0 IA T1b N0(mol+) M0 IA T1b N1 M0 IIA T1b N1a M0 IIA T1b N1b M0 IIA T1b N1c M0 IIA T1b N1mi M0 IB T1b N1NOS M0 IIA T1b N2a M0 IIIA T1b N2b M0 IIIA T1b N2NOS M0 IIIA T1b N3a M0 IIIC T1b N3b M0 IIIC T1b N3c M0 IIIC T1b N3NOS M0 IIIC T1b NX M0 UNK T1c N0 M0 IA T1c N0(i-) M0 IA T1c N0(i+) M0 IA T1c N0(mol-) M0 IA T1c N0(mol+) M0 IA T1c N1 M0 IIA T1c N1a M0 IIA T1c N1b M0 IIA T1c N1c M0 IIA T1c N1mi M0 IB T1c N1NOS M0 IIA T1c N2a M0 IIIA T1c N2b M0 IIIA T1c N2NOS M0 IIIA T1c N3a M0 IIIC T1c N3b M0 IIIC T1c N3c M0 IIIC T1c N3NOS M0 IIIC T1c NX M0 UNK T1NOS N0 M0 IA T1NOS N0(i-) M0 IA T1NOS N0(i+) M0 IA T1NOS N0(mol-) M0 IA T1NOS N0(mol+) M0 IA T1NOS N1 M0 IIA T1NOS N1a M0 IIA T1NOS N1b M0 IIA T1NOS N1c M0 IIA T1NOS N1mi M0 IB T1NOS N1NOS M0 IIA T1NOS N2a M0 IIIA T1NOS N2b M0 IIIA T1NOS N2NOS M0 IIIA T1NOS N3a M0 IIIC T1NOS N3b M0 IIIC T1NOS N3c M0 IIIC T1NOS N3NOS M0 IIIC T1NOS NX M0 UNK T2 N0 M0 IIA T2 N0(i-) M0 IIA T2 N0(i+) M0 IIA T2 N0(mol-) M0 IIA T2 N0(mol+) M0 IIA T2 N1 M0 IIB T2 N1a M0 IIB T2 N1b M0 IIB T2 N1c M0 IIB T2 N1mi M0 IIB T2 N1NOS M0 IIB T2 N2a M0 IIIA T2 N2b M0 IIIA T2 N2NOS M0 IIIA T2 N3a M0 IIIC T2 N3b M0 IIIC T2 N3c M0 IIIC T2 N3NOS M0 IIIC T2 NX M0 UNK T3 N0 M0 IIB T3 N0(i-) M0 IIB T3 N0(i+) M0 IIB T3 N0(mol-) M0 IIB T3 N0(mol+) M0 IIB T3 N1 M0 IIIA T3 N1a M0 IIIA T3 N1b M0 IIIA T3 N1c M0 IIIA T3 N1mi M0 IIIA T3 N1NOS M0 IIIA T3 N2a M0 IIIA T3 N2b M0 IIIA T3 N2NOS M0 IIIA T3 N3a M0 IIIC T3 N3b M0 IIIC T3 N3c M0 IIIC T3 N3NOS M0 IIIC T3 NX M0 UNK T4a N0 M0 IIIB T4a N0(i-) M0 IIIB T4a N0(i+) M0 IIIB T4a N0(mol-) M0 IIIB T4a N0(mol+) M0 IIIB T4a N1 M0 IIIB T4a N1a M0 IIIB T4a N1b M0 IIIB T4a N1c M0 IIIB T4a N1mi M0 IIIB T4a N1NOS M0 IIIB T4a N2a M0 IIIB T4a N2b M0 IIIB T4a N2NOS M0 IIIB T4a N3a M0 IIIC T4a N3b M0 IIIC T4a N3c M0 IIIC T4a N3NOS M0 IIIC T4a NX M0 IIINOS T4b N0 M0 IIIB T4b N0(i-) M0 IIIB T4b N0(i+) M0 IIIB T4b N0(mol-) M0 IIIB T4b N0(mol+) M0 IIIB T4b N1 M0 IIIB T4b N1a M0 IIIB T4b N1b M0 IIIB T4b N1c M0 IIIB T4b N1mi M0 IIIB T4b N1NOS M0 IIIB T4b N2a M0 IIIB T4b N2b M0 IIIB T4b N2NOS M0 IIIB T4b N3a M0 IIIC T4b N3b M0 IIIC T4b N3c M0 IIIC T4b N3NOS M0 IIIC T4b NX M0 IIINOS T4c N0 M0 IIIB T4c N0(i-) M0 IIIB T4c N0(i+) M0 IIIB T4c N0(mol-) M0 IIIB T4c N0(mol+) M0 IIIB T4c N1 M0 IIIB T4c N1a M0 IIIB T4c N1b M0 IIIB T4c N1c M0 IIIB T4c N1mi M0 IIIB T4c N1NOS M0 IIIB T4c N2a M0 IIIB T4c N2b M0 IIIB T4c N2NOS M0 IIIB T4c N3a M0 IIIC T4c N3b M0 IIIC T4c N3c M0 IIIC T4c N3NOS M0 IIIC T4c NX M0 IIINOS T4d N0 M0 IIIB T4d N0(i-) M0 IIIB T4d N0(i+) M0 IIIB T4d N0(mol-) M0 IIIB T4d N0(mol+) M0 IIIB T4d N1 M0 IIIB T4d N1a M0 IIIB T4d N1b M0 IIIB T4d N1c M0 IIIB T4d N1mi M0 IIIB T4d N1NOS M0 IIIB T4d N2a M0 IIIB T4d N2b M0 IIIB T4d N2NOS M0 IIIB T4d N3a M0 IIIC T4d N3b M0 IIIC T4d N3c M0 IIIC T4d N3NOS M0 IIIC T4d NX M0 IIINOS T4NOS N0 M0 IIIB T4NOS N0(i-) M0 IIIB T4NOS N0(i+) M0 IIIB T4NOS N0(mol-) M0 IIIB T4NOS N0(mol+) M0 IIIB T4NOS N1 M0 IIIB T4NOS N1a M0 IIIB T4NOS N1b M0 IIIB T4NOS N1c M0 IIIB T4NOS N1mi M0 IIIB T4NOS N1NOS M0 IIIB T4NOS N2a M0 IIIB T4NOS N2b M0 IIIB T4NOS N2NOS M0 IIIB T4NOS N3a M0 IIIC T4NOS N3b M0 IIIC T4NOS N3c M0 IIIC T4NOS N3NOS M0 IIIC T4NOS NX M0 IIINOS TX N0 M0 UNK TX N0(i-) M0 UNK TX N0(i+) M0 UNK TX N0(mol-) M0 UNK TX N0(mol+) M0 UNK TX N1 M0 UNK TX N1a M0 UNK TX N1b M0 UNK TX N1c M0 UNK TX N1mi M0 UNK TX N1NOS M0 UNK TX N2a M0 IIINOS TX N2b M0 IIINOS TX N2NOS M0 IIINOS TX N3a M0 IIIC TX N3b M0 IIIC TX N3c M0 IIIC TX N3NOS M0 IIIC TX NX M0 UNK T0 N0 M0(i+) ERROR T0 N0(i-) M0(i+) ERROR T0 N0(i+) M0(i+) ERROR T0 N0(mol-) M0(i+) ERROR T0 N0(mol+) M0(i+) ERROR T0 N1 M0(i+) IIA T0 N1a M0(i+) IIA T0 N1b M0(i+) IIA T0 N1c M0(i+) IIA T0 N1mi M0(i+) IB T0 N1NOS M0(i+) IIA T0 N2a M0(i+) IIIA T0 N2b M0(i+) IIIA T0 N2NOS M0(i+) IIIA T0 N3a M0(i+) IIIC T0 N3b M0(i+) IIIC T0 N3c M0(i+) IIIC T0 N3NOS M0(i+) IIIC T0 NX M0(i+) UNK Tis N0 M0(i+) 0 Tis N0(i-) M0(i+) 0 Tis N0(i+) M0(i+) 0 Tis N0(mol-) M0(i+) 0 Tis N0(mol+) M0(i+) 0 Tis N1 M0(i+) ERROR Tis N1a M0(i+) ERROR Tis N1b M0(i+) ERROR Tis N1c M0(i+) ERROR Tis N1mi M0(i+) ERROR Tis N1NOS M0(i+) ERROR Tis N2a M0(i+) ERROR Tis N2b M0(i+) ERROR Tis N2NOS M0(i+) ERROR Tis N3a M0(i+) ERROR Tis N3b M0(i+) ERROR Tis N3c M0(i+) ERROR Tis N3NOS M0(i+) ERROR Tis NX M0(i+) 0 T1mi N0 M0(i+) IA T1mi N0(i-) M0(i+) IA T1mi N0(i+) M0(i+) IA T1mi N0(mol-) M0(i+) IA T1mi N0(mol+) M0(i+) IA T1mi N1 M0(i+) IIA T1mi N1a M0(i+) IIA T1mi N1b M0(i+) IIA T1mi N1c M0(i+) IIA T1mi N1mi M0(i+) IB T1mi N1NOS M0(i+) IIA T1mi N2a M0(i+) IIIA T1mi N2b M0(i+) IIIA T1mi N2NOS M0(i+) IIIA T1mi N3a M0(i+) IIIC T1mi N3b M0(i+) IIIC T1mi N3c M0(i+) IIIC T1mi N3NOS M0(i+) IIIC T1mi NX M0(i+) UNK T1a N0 M0(i+) IA T1a N0(i-) M0(i+) IA T1a N0(i+) M0(i+) IA T1a N0(mol-) M0(i+) IA T1a N0(mol+) M0(i+) IA T1a N1 M0(i+) IIA T1a N1a M0(i+) IIA T1a N1b M0(i+) IIA T1a N1c M0(i+) IIA T1a N1mi M0(i+) IB T1a N1NOS M0(i+) IIA T1a N2a M0(i+) IIIA T1a N2b M0(i+) IIIA T1a N2NOS M0(i+) IIIA T1a N3a M0(i+) IIIC T1a N3b M0(i+) IIIC T1a N3c M0(i+) IIIC T1a N3NOS M0(i+) IIIC T1a NX M0(i+) UNK T1b N0 M0(i+) IA T1b N0(i-) M0(i+) IA T1b N0(i+) M0(i+) IA T1b N0(mol-) M0(i+) IA T1b N0(mol+) M0(i+) IA T1b N1 M0(i+) IIA T1b N1a M0(i+) IIA T1b N1b M0(i+) IIA T1b N1c M0(i+) IIA T1b N1mi M0(i+) IB T1b N1NOS M0(i+) IIA T1b N2a M0(i+) IIIA T1b N2b M0(i+) IIIA T1b N2NOS M0(i+) IIIA T1b N3a M0(i+) IIIC T1b N3b M0(i+) IIIC T1b N3c M0(i+) IIIC T1b N3NOS M0(i+) IIIC T1b NX M0(i+) UNK T1c N0 M0(i+) IA T1c N0(i-) M0(i+) IA T1c N0(i+) M0(i+) IA T1c N0(mol-) M0(i+) IA T1c N0(mol+) M0(i+) IA T1c N1 M0(i+) IIA T1c N1a M0(i+) IIA T1c N1b M0(i+) IIA T1c N1c M0(i+) IIA T1c N1mi M0(i+) IB T1c N1NOS M0(i+) IIA T1c N2a M0(i+) IIIA T1c N2b M0(i+) IIIA T1c N2NOS M0(i+) IIIA T1c N3a M0(i+) IIIC T1c N3b M0(i+) IIIC T1c N3c M0(i+) IIIC T1c N3NOS M0(i+) IIIC T1c NX M0(i+) UNK T1NOS N0 M0(i+) IA T1NOS N0(i-) M0(i+) IA T1NOS N0(i+) M0(i+) IA T1NOS N0(mol-) M0(i+) IA T1NOS N0(mol+) M0(i+) IA T1NOS N1 M0(i+) IIA T1NOS N1a M0(i+) IIA T1NOS N1b M0(i+) IIA T1NOS N1c M0(i+) IIA T1NOS N1mi M0(i+) IB T1NOS N1NOS M0(i+) IIA T1NOS N2a M0(i+) IIIA T1NOS N2b M0(i+) IIIA T1NOS N2NOS M0(i+) IIIA T1NOS N3a M0(i+) IIIC T1NOS N3b M0(i+) IIIC T1NOS N3c M0(i+) IIIC T1NOS N3NOS M0(i+) IIIC T1NOS NX M0(i+) UNK T2 N0 M0(i+) IIA T2 N0(i-) M0(i+) IIA T2 N0(i+) M0(i+) IIA T2 N0(mol-) M0(i+) IIA T2 N0(mol+) M0(i+) IIA T2 N1 M0(i+) IIB T2 N1a M0(i+) IIB T2 N1b M0(i+) IIB T2 N1c M0(i+) IIB T2 N1mi M0(i+) IIB T2 N1NOS M0(i+) IIB T2 N2a M0(i+) IIIA T2 N2b M0(i+) IIIA T2 N2NOS M0(i+) IIIA T2 N3a M0(i+) IIIC T2 N3b M0(i+) IIIC T2 N3c M0(i+) IIIC T2 N3NOS M0(i+) IIIC T2 NX M0(i+) UNK T3 N0 M0(i+) IIB T3 N0(i-) M0(i+) IIB T3 N0(i+) M0(i+) IIB T3 N0(mol-) M0(i+) IIB T3 N0(mol+) M0(i+) IIB T3 N1 M0(i+) IIIA T3 N1a M0(i+) IIIA T3 N1b M0(i+) IIIA T3 N1c M0(i+) IIIA T3 N1mi M0(i+) IIIA T3 N1NOS M0(i+) IIIA T3 N2a M0(i+) IIIA T3 N2b M0(i+) IIIA T3 N2NOS M0(i+) IIIA T3 N3a M0(i+) IIIC T3 N3b M0(i+) IIIC T3 N3c M0(i+) IIIC T3 N3NOS M0(i+) IIIC T3 NX M0(i+) UNK T4a N0 M0(i+) IIIB T4a N0(i-) M0(i+) IIIB T4a N0(i+) M0(i+) IIIB T4a N0(mol-) M0(i+) IIIB T4a N0(mol+) M0(i+) IIIB T4a N1 M0(i+) IIIB T4a N1a M0(i+) IIIB T4a N1b M0(i+) IIIB T4a N1c M0(i+) IIIB T4a N1mi M0(i+) IIIB T4a N1NOS M0(i+) IIIB T4a N2a M0(i+) IIIB T4a N2b M0(i+) IIIB T4a N2NOS M0(i+) IIIB T4a N3a M0(i+) IIIC T4a N3b M0(i+) IIIC T4a N3c M0(i+) IIIC T4a N3NOS M0(i+) IIIC T4a NX M0(i+) IIINOS T4b N0 M0(i+) IIIB T4b N0(i-) M0(i+) IIIB T4b N0(i+) M0(i+) IIIB T4b N0(mol-) M0(i+) IIIB T4b N0(mol+) M0(i+) IIIB T4b N1 M0(i+) IIIB T4b N1a M0(i+) IIIB T4b N1b M0(i+) IIIB T4b N1c M0(i+) IIIB T4b N1mi M0(i+) IIIB T4b N1NOS M0(i+) IIIB T4b N2a M0(i+) IIIB T4b N2b M0(i+) IIIB T4b N2NOS M0(i+) IIIB T4b N3a M0(i+) IIIC T4b N3b M0(i+) IIIC T4b N3c M0(i+) IIIC T4b N3NOS M0(i+) IIIC T4b NX M0(i+) IIINOS T4c N0 M0(i+) IIIB T4c N0(i-) M0(i+) IIIB T4c N0(i+) M0(i+) IIIB T4c N0(mol-) M0(i+) IIIB T4c N0(mol+) M0(i+) IIIB T4c N1 M0(i+) IIIB T4c N1a M0(i+) IIIB T4c N1b M0(i+) IIIB T4c N1c M0(i+) IIIB T4c N1mi M0(i+) IIIB T4c N1NOS M0(i+) IIIB T4c N2a M0(i+) IIIB T4c N2b M0(i+) IIIB T4c N2NOS M0(i+) IIIB T4c N3a M0(i+) IIIC T4c N3b M0(i+) IIIC T4c N3c M0(i+) IIIC T4c N3NOS M0(i+) IIIC T4c NX M0(i+) IIINOS T4d N0 M0(i+) IIIB T4d N0(i-) M0(i+) IIIB T4d N0(i+) M0(i+) IIIB T4d N0(mol-) M0(i+) IIIB T4d N0(mol+) M0(i+) IIIB T4d N1 M0(i+) IIIB T4d N1a M0(i+) IIIB T4d N1b M0(i+) IIIB T4d N1c M0(i+) IIIB T4d N1mi M0(i+) IIIB T4d N1NOS M0(i+) IIIB T4d N2a M0(i+) IIIB T4d N2b M0(i+) IIIB T4d N2NOS M0(i+) IIIB T4d N3a M0(i+) IIIC T4d N3b M0(i+) IIIC T4d N3c M0(i+) IIIC T4d N3NOS M0(i+) IIIC T4d NX M0(i+) IIINOS T4NOS N0 M0(i+) IIIB T4NOS N0(i-) M0(i+) IIIB T4NOS N0(i+) M0(i+) IIIB T4NOS N0(mol-) M0(i+) IIIB T4NOS N0(mol+) M0(i+) IIIB T4NOS N1 M0(i+) IIIB T4NOS N1a M0(i+) IIIB T4NOS N1b M0(i+) IIIB T4NOS N1c M0(i+) IIIB T4NOS N1mi M0(i+) IIIB T4NOS N1NOS M0(i+) IIIB T4NOS N2a M0(i+) IIIB T4NOS N2b M0(i+) IIIB T4NOS N2NOS M0(i+) IIIB T4NOS N3a M0(i+) IIIC T4NOS N3b M0(i+) IIIC T4NOS N3c M0(i+) IIIC T4NOS N3NOS M0(i+) IIIC T4NOS NX M0(i+) IIINOS TX N0 M0(i+) UNK TX N0(i-) M0(i+) UNK TX N0(i+) M0(i+) UNK TX N0(mol-) M0(i+) UNK TX N0(mol+) M0(i+) UNK TX N1 M0(i+) UNK TX N1a M0(i+) UNK TX N1b M0(i+) UNK TX N1c M0(i+) UNK TX N1mi M0(i+) UNK TX N1NOS M0(i+) UNK TX N2a M0(i+) IIINOS TX N2b M0(i+) IIINOS TX N2NOS M0(i+) IIINOS TX N3a M0(i+) IIIC TX N3b M0(i+) IIIC TX N3c M0(i+) IIIC TX N3NOS M0(i+) IIIC TX NX M0(i+) UNK T0 N0 M1 IV T0 N0(i-) M1 IV T0 N0(i+) M1 IV T0 N0(mol-) M1 IV T0 N0(mol+) M1 IV T0 N1 M1 IV T0 N1a M1 IV T0 N1b M1 IV T0 N1c M1 IV T0 N1mi M1 IV T0 N1NOS M1 IV T0 N2a M1 IV T0 N2b M1 IV T0 N2NOS M1 IV T0 N3a M1 IV T0 N3b M1 IV T0 N3c M1 IV T0 N3NOS M1 IV T0 NX M1 IV Tis N0 M1 ERROR Tis N0(i-) M1 ERROR Tis N0(i+) M1 ERROR Tis N0(mol-) M1 ERROR Tis N0(mol+) M1 ERROR Tis N1 M1 ERROR Tis N1a M1 ERROR Tis N1b M1 ERROR Tis N1c M1 ERROR Tis N1mi M1 ERROR Tis N1NOS M1 ERROR Tis N2a M1 ERROR Tis N2b M1 ERROR Tis N2NOS M1 ERROR Tis N3a M1 ERROR Tis N3b M1 ERROR Tis N3c M1 ERROR Tis N3NOS M1 ERROR Tis NX M1 ERROR T1mi N0 M1 IV T1mi N0(i-) M1 IV T1mi N0(i+) M1 IV T1mi N0(mol-) M1 IV T1mi N0(mol+) M1 IV T1mi N1 M1 IV T1mi N1a M1 IV T1mi N1b M1 IV T1mi N1c M1 IV T1mi N1mi M1 IV T1mi N1NOS M1 IV T1mi N2a M1 IV T1mi N2b M1 IV T1mi N2NOS M1 IV T1mi N3a M1 IV T1mi N3b M1 IV T1mi N3c M1 IV T1mi N3NOS M1 IV T1mi NX M1 IV T1a N0 M1 IV T1a N0(i-) M1 IV T1a N0(i+) M1 IV T1a N0(mol-) M1 IV T1a N0(mol+) M1 IV T1a N1 M1 IV T1a N1a M1 IV T1a N1b M1 IV T1a N1c M1 IV T1a N1mi M1 IV T1a N1NOS M1 IV T1a N2a M1 IV T1a N2b M1 IV T1a N2NOS M1 IV T1a N3a M1 IV T1a N3b M1 IV T1a N3c M1 IV T1a N3NOS M1 IV T1a NX M1 IV T1b N0 M1 IV T1b N0(i-) M1 IV T1b N0(i+) M1 IV T1b N0(mol-) M1 IV T1b N0(mol+) M1 IV T1b N1 M1 IV T1b N1a M1 IV T1b N1b M1 IV T1b N1c M1 IV T1b N1mi M1 IV T1b N1NOS M1 IV T1b N2a M1 IV T1b N2b M1 IV T1b N2NOS M1 IV T1b N3a M1 IV T1b N3b M1 IV T1b N3c M1 IV T1b N3NOS M1 IV T1b NX M1 IV T1c N0 M1 IV T1c N0(i-) M1 IV T1c N0(i+) M1 IV T1c N0(mol-) M1 IV T1c N0(mol+) M1 IV T1c N1 M1 IV T1c N1a M1 IV T1c N1b M1 IV T1c N1c M1 IV T1c N1mi M1 IV T1c N1NOS M1 IV T1c N2a M1 IV T1c N2b M1 IV T1c N2NOS M1 IV T1c N3a M1 IV T1c N3b M1 IV T1c N3c M1 IV T1c N3NOS M1 IV T1c NX M1 IV T1NOS N0 M1 IV T1NOS N0(i-) M1 IV T1NOS N0(i+) M1 IV T1NOS N0(mol-) M1 IV T1NOS N0(mol+) M1 IV T1NOS N1 M1 IV T1NOS N1a M1 IV T1NOS N1b M1 IV T1NOS N1c M1 IV T1NOS N1mi M1 IV T1NOS N1NOS M1 IV T1NOS N2a M1 IV T1NOS N2b M1 IV T1NOS N2NOS M1 IV T1NOS N3a M1 IV T1NOS N3b M1 IV T1NOS N3c M1 IV T1NOS N3NOS M1 IV T1NOS NX M1 IV T2 N0 M1 IV T2 N0(i-) M1 IV T2 N0(i+) M1 IV T2 N0(mol-) M1 IV T2 N0(mol+) M1 IV T2 N1 M1 IV T2 N1a M1 IV T2 N1b M1 IV T2 N1c M1 IV T2 N1mi M1 IV T2 N1NOS M1 IV T2 N2a M1 IV T2 N2b M1 IV T2 N2NOS M1 IV T2 N3a M1 IV T2 N3b M1 IV T2 N3c M1 IV T2 N3NOS M1 IV T2 NX M1 IV T3 N0 M1 IV T3 N0(i-) M1 IV T3 N0(i+) M1 IV T3 N0(mol-) M1 IV T3 N0(mol+) M1 IV T3 N1 M1 IV T3 N1a M1 IV T3 N1b M1 IV T3 N1c M1 IV T3 N1mi M1 IV T3 N1NOS M1 IV T3 N2a M1 IV T3 N2b M1 IV T3 N2NOS M1 IV T3 N3a M1 IV T3 N3b M1 IV T3 N3c M1 IV T3 N3NOS M1 IV T3 NX M1 IV T4a N0 M1 IV T4a N0(i-) M1 IV T4a N0(i+) M1 IV T4a N0(mol-) M1 IV T4a N0(mol+) M1 IV T4a N1 M1 IV T4a N1a M1 IV T4a N1b M1 IV T4a N1c M1 IV T4a N1mi M1 IV T4a N1NOS M1 IV T4a N2a M1 IV T4a N2b M1 IV T4a N2NOS M1 IV T4a N3a M1 IV T4a N3b M1 IV T4a N3c M1 IV T4a N3NOS M1 IV T4a NX M1 IV T4b N0 M1 IV T4b N0(i-) M1 IV T4b N0(i+) M1 IV T4b N0(mol-) M1 IV T4b N0(mol+) M1 IV T4b N1 M1 IV T4b N1a M1 IV T4b N1b M1 IV T4b N1c M1 IV T4b N1mi M1 IV T4b N1NOS M1 IV T4b N2a M1 IV T4b N2b M1 IV T4b N2NOS M1 IV T4b N3a M1 IV T4b N3b M1 IV T4b N3c M1 IV T4b N3NOS M1 IV T4b NX M1 IV T4c N0 M1 IV T4c N0(i-) M1 IV T4c N0(i+) M1 IV T4c N0(mol-) M1 IV T4c N0(mol+) M1 IV T4c N1 M1 IV T4c N1a M1 IV T4c N1b M1 IV T4c N1c M1 IV T4c N1mi M1 IV T4c N1NOS M1 IV T4c N2a M1 IV T4c N2b M1 IV T4c N2NOS M1 IV T4c N3a M1 IV T4c N3b M1 IV T4c N3c M1 IV T4c N3NOS M1 IV T4c NX M1 IV T4d N0 M1 IV T4d N0(i-) M1 IV T4d N0(i+) M1 IV T4d N0(mol-) M1 IV T4d N0(mol+) M1 IV T4d N1 M1 IV T4d N1a M1 IV T4d N1b M1 IV T4d N1c M1 IV T4d N1mi M1 IV T4d N1NOS M1 IV T4d N2a M1 IV T4d N2b M1 IV T4d N2NOS M1 IV T4d N3a M1 IV T4d N3b M1 IV T4d N3c M1 IV T4d N3NOS M1 IV T4d NX M1 IV T4NOS N0 M1 IV T4NOS N0(i-) M1 IV T4NOS N0(i+) M1 IV T4NOS N0(mol-) M1 IV T4NOS N0(mol+) M1 IV T4NOS N1 M1 IV T4NOS N1a M1 IV T4NOS N1b M1 IV T4NOS N1c M1 IV T4NOS N1mi M1 IV T4NOS N1NOS M1 IV T4NOS N2a M1 IV T4NOS N2b M1 IV T4NOS N2NOS M1 IV T4NOS N3a M1 IV T4NOS N3b M1 IV T4NOS N3c M1 IV T4NOS N3NOS M1 IV T4NOS NX M1 IV TX N0 M1 IV TX N0(i-) M1 IV TX N0(i+) M1 IV TX N0(mol-) M1 IV TX N0(mol+) M1 IV TX N1 M1 IV TX N1a M1 IV TX N1b M1 IV TX N1c M1 IV TX N1mi M1 IV TX N1NOS M1 IV TX N2a M1 IV TX N2b M1 IV TX N2NOS M1 IV TX N3a M1 IV TX N3b M1 IV TX N3c M1 IV TX N3NOS M1 IV TX NX M1 IV AJCC TNM 6 Stage T N M Stage T0 N0 M0 ERROR T0 N0(i-) M0 ERROR T0 N0(i+) M0 ERROR T0 N0(mol-) M0 ERROR T0 N0(mol+) M0 ERROR T0 N1 M0 IIA T0 N1NOS M0 IIA T0 N1a M0 IIA T0 N1b M0 IIA T0 N1c M0 IIA T0 N1mi M0 IIA T0 N2NOS M0 IIIA T0 N2a M0 IIIA T0 N2b M0 IIIA T0 N3NOS M0 IIIC T0 N3a M0 IIIC T0 N3b M0 IIIC T0 N3c M0 IIIC T0 NX M0 UNK T0 N0 M1 IV T0 N0(i-) M1 IV T0 N0(i+) M1 IV T0 N0(mol-) M1 IV T0 N0(mol+) M1 IV T0 N1 M1 IV T0 N1NOS M1 IV T0 N1a M1 IV T0 N1b M1 IV T0 N1c M1 IV T0 N1mi M1 IV T0 N2NOS M1 IV T0 N2a M1 IV T0 N2b M1 IV T0 N3NOS M1 IV T0 N3a M1 IV T0 N3b M1 IV T0 N3c M1 IV T0 NX M1 IV T0 N0 MX UNK T0 N0(i-) MX UNK T0 N0(i+) MX UNK T0 N0(mol-) MX UNK T0 N0(mol+) MX UNK T0 N1 MX UNK T0 N1NOS MX UNK T0 N1a MX UNK T0 N1b MX UNK T0 N1c MX UNK T0 N1mi MX UNK T0 N2NOS MX UNK T0 N2a MX UNK T0 N2b MX UNK T0 N3NOS MX UNK T0 N3a MX UNK T0 N3b MX UNK T0 N3c MX UNK T0 NX MX UNK Tis N0 M0 0 Tis N0(i-) M0 0 Tis N0(i+) M0 0 Tis N0(mol-) M0 0 Tis N0(mol+) M0 0 Tis N1 M0 IIA Tis N1NOS M0 IIA Tis N1a M0 IIA Tis N1b M0 IIA Tis N1c M0 IIA Tis N1mi M0 IIA Tis N2NOS M0 IIIA Tis N2a M0 IIIA Tis N2b M0 IIIA Tis N3NOS M0 IIIC Tis N3a M0 IIIC Tis N3b M0 IIIC Tis N3c M0 IIIC Tis NX M0 0 Tis N0 M1 IV Tis N0(i-) M1 IV Tis N0(i+) M1 IV Tis N0(mol-) M1 IV Tis N0(mol+) M1 IV Tis N1 M1 IV Tis N1NOS M1 IV Tis N1a M1 IV Tis N1b M1 IV Tis N1c M1 IV Tis N1mi M1 IV Tis N2NOS M1 IV Tis N2a M1 IV Tis N2b M1 IV Tis N3NOS M1 IV Tis N3a M1 IV Tis N3b M1 IV Tis N3c M1 IV Tis NX M1 IV Tis N0 MX 0 Tis N0(i-) MX 0 Tis N0(i+) MX 0 Tis N0(mol-) MX 0 Tis N0(mol+) MX 0 Tis N1 MX IIA Tis N1NOS MX IIA Tis N1a MX IIA Tis N1b MX IIA Tis N1c MX IIA Tis N1mi MX IIA Tis N2NOS MX IIIA Tis N2a MX IIIA Tis N2b MX IIIA Tis N3NOS MX IIIC Tis N3a MX IIIC Tis N3b MX IIIC Tis N3c MX IIIC Tis NX MX 0 T1NOS N0 M0 I T1NOS N0(i-) M0 I T1NOS N0(i+) M0 I T1NOS N0(mol-) M0 I T1NOS N0(mol+) M0 I T1NOS N1 M0 IIA T1NOS N1NOS M0 IIA T1NOS N1a M0 IIA T1NOS N1b M0 IIA T1NOS N1c M0 IIA T1NOS N1mi M0 IIA T1NOS N2NOS M0 IIIA T1NOS N2a M0 IIIA T1NOS N2b M0 IIIA T1NOS N3NOS M0 IIIC T1NOS N3a M0 IIIC T1NOS N3b M0 IIIC T1NOS N3c M0 IIIC T1NOS NX M0 UNK T1NOS N0 M1 IV T1NOS N0(i-) M1 IV T1NOS N0(i+) M1 IV T1NOS N0(mol-) M1 IV T1NOS N0(mol+) M1 IV T1NOS N1 M1 IV T1NOS N1NOS M1 IV T1NOS N1a M1 IV T1NOS N1b M1 IV T1NOS N1c M1 IV T1NOS N1mi M1 IV T1NOS N2NOS M1 IV T1NOS N2a M1 IV T1NOS N2b M1 IV T1NOS N3NOS M1 IV T1NOS N3a M1 IV T1NOS N3b M1 IV T1NOS N3c M1 IV T1NOS NX M1 IV T1NOS N0 MX UNK T1NOS N0(i-) MX UNK T1NOS N0(i+) MX UNK T1NOS N0(mol-) MX UNK T1NOS N0(mol+) MX UNK T1NOS N1 MX UNK T1NOS N1NOS MX UNK T1NOS N1a MX UNK T1NOS N1b MX UNK T1NOS N1c MX UNK T1NOS N1mi MX UNK T1NOS N2NOS MX UNK T1NOS N2a MX UNK T1NOS N2b MX UNK T1NOS N3NOS MX UNK T1NOS N3a MX UNK T1NOS N3b MX UNK T1NOS N3c MX UNK T1NOS NX MX UNK T1mi N0 M0 I T1mi N0(i-) M0 I T1mi N0(i+) M0 I T1mi N0(mol-) M0 I T1mi N0(mol+) M0 I T1mi N1 M0 IIA T1mi N1NOS M0 IIA T1mi N1a M0 IIA T1mi N1b M0 IIA T1mi N1c M0 IIA T1mi N1mi M0 IIA T1mi N2NOS M0 IIIA T1mi N2a M0 IIIA T1mi N2b M0 IIIA T1mi N3NOS M0 IIIC T1mi N3a M0 IIIC T1mi N3b M0 IIIC T1mi N3c M0 IIIC T1mi NX M0 UNK T1mi N0 M1 IV T1mi N0(i-) M1 IV T1mi N0(i+) M1 IV T1mi N0(mol-) M1 IV T1mi N0(mol+) M1 IV T1mi N1 M1 IV T1mi N1NOS M1 IV T1mi N1a M1 IV T1mi N1b M1 IV T1mi N1c M1 IV T1mi N1mi M1 IV T1mi N2NOS M1 IV T1mi N2a M1 IV T1mi N2b M1 IV T1mi N3NOS M1 IV T1mi N3a M1 IV T1mi N3b M1 IV T1mi N3c M1 IV T1mi NX M1 IV T1mi N0 MX UNK T1mi N0(i-) MX UNK T1mi N0(i+) MX UNK T1mi N0(mol-) MX UNK T1mi N0(mol+) MX UNK T1mi N1 MX UNK T1mi N1NOS MX UNK T1mi N1a MX UNK T1mi N1b MX UNK T1mi N1c MX UNK T1mi N1mi MX UNK T1mi N2NOS MX UNK T1mi N2a MX UNK T1mi N2b MX UNK T1mi N3NOS MX UNK T1mi N3a MX UNK T1mi N3b MX UNK T1mi N3c MX UNK T1mi NX MX UNK T1a N0 M0 I T1a N0(i-) M0 I T1a N0(i+) M0 I T1a N0(mol-) M0 I T1a N0(mol+) M0 I T1a N1 M0 IIA T1a N1NOS M0 IIA T1a N1a M0 IIA T1a N1b M0 IIA T1a N1c M0 IIA T1a N1mi M0 IIA T1a N2NOS M0 IIIA T1a N2a M0 IIIA T1a N2b M0 IIIA T1a N3NOS M0 IIIC T1a N3a M0 IIIC T1a N3b M0 IIIC T1a N3c M0 IIIC T1a NX M0 UNK T1a N0 M1 IV T1a N0(i-) M1 IV T1a N0(i+) M1 IV T1a N0(mol-) M1 IV T1a N0(mol+) M1 IV T1a N1 M1 IV T1a N1NOS M1 IV T1a N1a M1 IV T1a N1b M1 IV T1a N1c M1 IV T1a N1mi M1 IV T1a N2NOS M1 IV T1a N2a M1 IV T1a N2b M1 IV T1a N3NOS M1 IV T1a N3a M1 IV T1a N3b M1 IV T1a N3c M1 IV T1a NX M1 IV T1a N0 MX UNK T1a N0(i-) MX UNK T1a N0(i+) MX UNK T1a N0(mol-) MX UNK T1a N0(mol+) MX UNK T1a N1 MX UNK T1a N1NOS MX UNK T1a N1a MX UNK T1a N1b MX UNK T1a N1c MX UNK T1a N1mi MX UNK T1a N2NOS MX UNK T1a N2a MX UNK T1a N2b MX UNK T1a N3NOS MX UNK T1a N3a MX UNK T1a N3b MX UNK T1a N3c MX UNK T1a NX MX UNK T1b N0 M0 I T1b N0(i-) M0 I T1b N0(i+) M0 I T1b N0(mol-) M0 I T1b N0(mol+) M0 I T1b N1 M0 IIA T1b N1NOS M0 IIA T1b N1a M0 IIA T1b N1b M0 IIA T1b N1c M0 IIA T1b N1mi M0 IIA T1b N2NOS M0 IIIA T1b N2a M0 IIIA T1b N2b M0 IIIA T1b N3NOS M0 IIIC T1b N3a M0 IIIC T1b N3b M0 IIIC T1b N3c M0 IIIC T1b NX M0 UNK T1b N0 M1 IV T1b N0(i-) M1 IV T1b N0(i+) M1 IV T1b N0(mol-) M1 IV T1b N0(mol+) M1 IV T1b N1 M1 IV T1b N1NOS M1 IV T1b N1a M1 IV T1b N1b M1 IV T1b N1c M1 IV T1b N1mi M1 IV T1b N2NOS M1 IV T1b N2a M1 IV T1b N2b M1 IV T1b N3NOS M1 IV T1b N3a M1 IV T1b N3b M1 IV T1b N3c M1 IV T1b NX M1 IV T1b N0 MX UNK T1b N0(i-) MX UNK T1b N0(i+) MX UNK T1b N0(mol-) MX UNK T1b N0(mol+) MX UNK T1b N1 MX UNK T1b N1NOS MX UNK T1b N1a MX UNK T1b N1b MX UNK T1b N1c MX UNK T1b N1mi MX UNK T1b N2NOS MX UNK T1b N2a MX UNK T1b N2b MX UNK T1b N3NOS MX UNK T1b N3a MX UNK T1b N3b MX UNK T1b N3c MX UNK T1b NX MX UNK T1c N0 M0 I T1c N0(i-) M0 I T1c N0(i+) M0 I T1c N0(mol-) M0 I T1c N0(mol+) M0 I T1c N1 M0 IIA T1c N1NOS M0 IIA T1c N1a M0 IIA T1c N1b M0 IIA T1c N1c M0 IIA T1c N1mi M0 IIA T1c N2NOS M0 IIIA T1c N2a M0 IIIA T1c N2b M0 IIIA T1c N3NOS M0 IIIC T1c N3a M0 IIIC T1c N3b M0 IIIC T1c N3c M0 IIIC T1c NX M0 UNK T1c N0 M1 IV T1c N0(i-) M1 IV T1c N0(i+) M1 IV T1c N0(mol-) M1 IV T1c N0(mol+) M1 IV T1c N1 M1 IV T1c N1NOS M1 IV T1c N1a M1 IV T1c N1b M1 IV T1c N1c M1 IV T1c N1mi M1 IV T1c N2NOS M1 IV T1c N2a M1 IV T1c N2b M1 IV T1c N3NOS M1 IV T1c N3a M1 IV T1c N3b M1 IV T1c N3c M1 IV T1c NX M1 IV T1c N0 MX UNK T1c N0(i-) MX UNK T1c N0(i+) MX UNK T1c N0(mol-) MX UNK T1c N0(mol+) MX UNK T1c N1 MX UNK T1c N1NOS MX UNK T1c N1a MX UNK T1c N1b MX UNK T1c N1c MX UNK T1c N1mi MX UNK T1c N2NOS MX UNK T1c N2a MX UNK T1c N2b MX UNK T1c N3NOS MX UNK T1c N3a MX UNK T1c N3b MX UNK T1c N3c MX UNK T1c NX MX UNK T2 N0 M0 IIA T2 N0(i-) M0 IIA T2 N0(i+) M0 IIA T2 N0(mol-) M0 IIA T2 N0(mol+) M0 IIA T2 N1 M0 IIB T2 N1NOS M0 IIB T2 N1a M0 IIB T2 N1b M0 IIB T2 N1c M0 IIB T2 N1mi M0 IIB T2 N2NOS M0 IIIA T2 N2a M0 IIIA T2 N2b M0 IIIA T2 N3NOS M0 IIIC T2 N3a M0 IIIC T2 N3b M0 IIIC T2 N3c M0 IIIC T2 NX M0 UNK T2 N0 M1 IV T2 N0(i-) M1 IV T2 N0(i+) M1 IV T2 N0(mol-) M1 IV T2 N0(mol+) M1 IV T2 N1 M1 IV T2 N1NOS M1 IV T2 N1a M1 IV T2 N1b M1 IV T2 N1c M1 IV T2 N1mi M1 IV T2 N2NOS M1 IV T2 N2a M1 IV T2 N2b M1 IV T2 N3NOS M1 IV T2 N3a M1 IV T2 N3b M1 IV T2 N3c M1 IV T2 NX M1 IV T2 N0 MX UNK T2 N0(i-) MX UNK T2 N0(i+) MX UNK T2 N0(mol-) MX UNK T2 N0(mol+) MX UNK T2 N1 MX UNK T2 N1NOS MX UNK T2 N1a MX UNK T2 N1b MX UNK T2 N1c MX UNK T2 N1mi MX UNK T2 N2NOS MX UNK T2 N2a MX UNK T2 N2b MX UNK T2 N3NOS MX UNK T2 N3a MX UNK T2 N3b MX UNK T2 N3c MX UNK T2 NX MX UNK T3 N0 M0 IIB T3 N0(i-) M0 IIB T3 N0(i+) M0 IIB T3 N0(mol-) M0 IIB T3 N0(mol+) M0 IIB T3 N1 M0 IIIA T3 N1NOS M0 IIIA T3 N1a M0 IIIA T3 N1b M0 IIIA T3 N1c M0 IIIA T3 N1mi M0 IIIA T3 N2NOS M0 IIIA T3 N2a M0 IIIA T3 N2b M0 IIIA T3 N3NOS M0 IIIC T3 N3a M0 IIIC T3 N3b M0 IIIC T3 N3c M0 IIIC T3 NX M0 UNK T3 N0 M1 IV T3 N0(i-) M1 IV T3 N0(i+) M1 IV T3 N0(mol-) M1 IV T3 N0(mol+) M1 IV T3 N1 M1 IV T3 N1NOS M1 IV T3 N1a M1 IV T3 N1b M1 IV T3 N1c M1 IV T3 N1mi M1 IV T3 N2NOS M1 IV T3 N2a M1 IV T3 N2b M1 IV T3 N3NOS M1 IV T3 N3a M1 IV T3 N3b M1 IV T3 N3c M1 IV T3 NX M1 IV T3 N0 MX UNK T3 N0(i-) MX UNK T3 N0(i+) MX UNK T3 N0(mol-) MX UNK T3 N0(mol+) MX UNK T3 N1 MX UNK T3 N1NOS MX UNK T3 N1a MX UNK T3 N1b MX UNK T3 N1c MX UNK T3 N1mi MX UNK T3 N2NOS MX UNK T3 N2a MX UNK T3 N2b MX UNK T3 N3NOS MX UNK T3 N3a MX UNK T3 N3b MX UNK T3 N3c MX UNK T3 NX MX UNK T4NOS N0 M0 IIIB T4NOS N0(i-) M0 IIIB T4NOS N0(i+) M0 IIIB T4NOS N0(mol-) M0 IIIB T4NOS N0(mol+) M0 IIIB T4NOS N1 M0 IIIB T4NOS N1NOS M0 IIIB T4NOS N1a M0 IIIB T4NOS N1b M0 IIIB T4NOS N1c M0 IIIB T4NOS N1mi M0 IIIB T4NOS N2NOS M0 IIIB T4NOS N2a M0 IIIB T4NOS N2b M0 IIIB T4NOS N3NOS M0 IIIC T4NOS N3a M0 IIIC T4NOS N3b M0 IIIC T4NOS N3c M0 IIIC T4NOS NX M0 IIINOS T4NOS N0 M1 IV T4NOS N0(i-) M1 IV T4NOS N0(i+) M1 IV T4NOS N0(mol-) M1 IV T4NOS N0(mol+) M1 IV T4NOS N1 M1 IV T4NOS N1NOS M1 IV T4NOS N1a M1 IV T4NOS N1b M1 IV T4NOS N1c M1 IV T4NOS N1mi M1 IV T4NOS N2NOS M1 IV T4NOS N2a M1 IV T4NOS N2b M1 IV T4NOS N3NOS M1 IV T4NOS N3a M1 IV T4NOS N3b M1 IV T4NOS N3c M1 IV T4NOS NX M1 IV T4NOS N0 MX UNK T4NOS N0(i-) MX UNK T4NOS N0(i+) MX UNK T4NOS N0(mol-) MX UNK T4NOS N0(mol+) MX UNK T4NOS N1 MX UNK T4NOS N1NOS MX UNK T4NOS N1a MX UNK T4NOS N1b MX UNK T4NOS N1c MX UNK T4NOS N1mi MX UNK T4NOS N2NOS MX UNK T4NOS N2a MX UNK T4NOS N2b MX UNK T4NOS N3NOS MX UNK T4NOS N3a MX UNK T4NOS N3b MX UNK T4NOS N3c MX UNK T4NOS NX MX UNK T4a N0 M0 IIIB T4a N0(i-) M0 IIIB T4a N0(i+) M0 IIIB T4a N0(mol-) M0 IIIB T4a N0(mol+) M0 IIIB T4a N1 M0 IIIB T4a N1NOS M0 IIIB T4a N1a M0 IIIB T4a N1b M0 IIIB T4a N1c M0 IIIB T4a N1mi M0 IIIB T4a N2NOS M0 IIIB T4a N2a M0 IIIB T4a N2b M0 IIIB T4a N3NOS M0 IIIC T4a N3a M0 IIIC T4a N3b M0 IIIC T4a N3c M0 IIIC T4a NX M0 IIINOS T4a N0 M1 IV T4a N0(i-) M1 IV T4a N0(i+) M1 IV T4a N0(mol-) M1 IV T4a N0(mol+) M1 IV T4a N1 M1 IV T4a N1NOS M1 IV T4a N1a M1 IV T4a N1b M1 IV T4a N1c M1 IV T4a N1mi M1 IV T4a N2NOS M1 IV T4a N2a M1 IV T4a N2b M1 IV T4a N3NOS M1 IV T4a N3a M1 IV T4a N3b M1 IV T4a N3c M1 IV T4a NX M1 IV T4a N0 MX UNK T4a N0(i-) MX UNK T4a N0(i+) MX UNK T4a N0(mol-) MX UNK T4a N0(mol+) MX UNK T4a N1 MX UNK T4a N1NOS MX UNK T4a N1a MX UNK T4a N1b MX UNK T4a N1c MX UNK T4a N1mi MX UNK T4a N2NOS MX UNK T4a N2a MX UNK T4a N2b MX UNK T4a N3NOS MX UNK T4a N3a MX UNK T4a N3b MX UNK T4a N3c MX UNK T4a NX MX UNK T4b N0 M0 IIIB T4b N0(i-) M0 IIIB T4b N0(i+) M0 IIIB T4b N0(mol-) M0 IIIB T4b N0(mol+) M0 IIIB T4b N1 M0 IIIB T4b N1NOS M0 IIIB T4b N1a M0 IIIB T4b N1b M0 IIIB T4b N1c M0 IIIB T4b N1mi M0 IIIB T4b N2NOS M0 IIIB T4b N2a M0 IIIB T4b N2b M0 IIIB T4b N3NOS M0 IIIC T4b N3a M0 IIIC T4b N3b M0 IIIC T4b N3c M0 IIIC T4b NX M0 IIINOS T4b N0 M1 IV T4b N0(i-) M1 IV T4b N0(i+) M1 IV T4b N0(mol-) M1 IV T4b N0(mol+) M1 IV T4b N1 M1 IV T4b N1NOS M1 IV T4b N1a M1 IV T4b N1b M1 IV T4b N1c M1 IV T4b N1mi M1 IV T4b N2NOS M1 IV T4b N2a M1 IV T4b N2b M1 IV T4b N3NOS M1 IV T4b N3a M1 IV T4b N3b M1 IV T4b N3c M1 IV T4b NX M1 IV T4b N0 MX UNK T4b N0(i-) MX UNK T4b N0(i+) MX UNK T4b N0(mol-) MX UNK T4b N0(mol+) MX UNK T4b N1 MX UNK T4b N1NOS MX UNK T4b N1a MX UNK T4b N1b MX UNK T4b N1c MX UNK T4b N1mi MX UNK T4b N2NOS MX UNK T4b N2a MX UNK T4b N2b MX UNK T4b N3NOS MX UNK T4b N3a MX UNK T4b N3b MX UNK T4b N3c MX UNK T4b NX MX UNK T4c N0 M0 IIIB T4c N0(i-) M0 IIIB T4c N0(i+) M0 IIIB T4c N0(mol-) M0 IIIB T4c N0(mol+) M0 IIIB T4c N1 M0 IIIB T4c N1NOS M0 IIIB T4c N1a M0 IIIB T4c N1b M0 IIIB T4c N1c M0 IIIB T4c N1mi M0 IIIB T4c N2NOS M0 IIIB T4c N2a M0 IIIB T4c N2b M0 IIIB T4c N3NOS M0 IIIC T4c N3a M0 IIIC T4c N3b M0 IIIC T4c N3c M0 IIIC T4c NX M0 IIINOS T4c N0 M1 IV T4c N0(i-) M1 IV T4c N0(i+) M1 IV T4c N0(mol-) M1 IV T4c N0(mol+) M1 IV T4c N1 M1 IV T4c N1NOS M1 IV T4c N1a M1 IV T4c N1b M1 IV T4c N1c M1 IV T4c N1mi M1 IV T4c N2NOS M1 IV T4c N2a M1 IV T4c N2b M1 IV T4c N3NOS M1 IV T4c N3a M1 IV T4c N3b M1 IV T4c N3c M1 IV T4c NX M1 IV T4c N0 MX UNK T4c N0(i-) MX UNK T4c N0(i+) MX UNK T4c N0(mol-) MX UNK T4c N0(mol+) MX UNK T4c N1 MX UNK T4c N1NOS MX UNK T4c N1a MX UNK T4c N1b MX UNK T4c N1c MX UNK T4c N1mi MX UNK T4c N2NOS MX UNK T4c N2a MX UNK T4c N2b MX UNK T4c N3NOS MX UNK T4c N3a MX UNK T4c N3b MX UNK T4c N3c MX UNK T4c NX MX UNK T4d N0 M0 IIIB T4d N0(i-) M0 IIIB T4d N0(i+) M0 IIIB T4d N0(mol-) M0 IIIB T4d N0(mol+) M0 IIIB T4d N1 M0 IIIB T4d N1NOS M0 IIIB T4d N1a M0 IIIB T4d N1b M0 IIIB T4d N1c M0 IIIB T4d N1mi M0 IIIB T4d N2NOS M0 IIIB T4d N2a M0 IIIB T4d N2b M0 IIIB T4d N3NOS M0 IIIC T4d N3a M0 IIIC T4d N3b M0 IIIC T4d N3c M0 IIIC T4d NX M0 IIINOS T4d N0 M1 IV T4d N0(i-) M1 IV T4d N0(i+) M1 IV T4d N0(mol-) M1 IV T4d N0(mol+) M1 IV T4d N1 M1 IV T4d N1NOS M1 IV T4d N1a M1 IV T4d N1b M1 IV T4d N1c M1 IV T4d N1mi M1 IV T4d N2NOS M1 IV T4d N2a M1 IV T4d N2b M1 IV T4d N3NOS M1 IV T4d N3a M1 IV T4d N3b M1 IV T4d N3c M1 IV T4d NX M1 IV T4d N0 MX UNK T4d N0(i-) MX UNK T4d N0(i+) MX UNK T4d N0(mol-) MX UNK T4d N0(mol+) MX UNK T4d N1 MX UNK T4d N1NOS MX UNK T4d N1a MX UNK T4d N1b MX UNK T4d N1c MX UNK T4d N1mi MX UNK T4d N2NOS MX UNK T4d N2a MX UNK T4d N2b MX UNK T4d N3NOS MX UNK T4d N3a MX UNK T4d N3b MX UNK T4d N3c MX UNK T4d NX MX UNK TX N0 M0 UNK TX N0(i-) M0 UNK TX N0(i+) M0 UNK TX N0(mol-) M0 UNK TX N0(mol+) M0 UNK TX N1 M0 UNK TX N1NOS M0 UNK TX N1a M0 UNK TX N1b M0 UNK TX N1c M0 UNK TX N1mi M0 UNK TX N2NOS M0 IIINOS TX N2a M0 IIINOS TX N2b M0 IIINOS TX N3NOS M0 IIIC TX N3a M0 IIIC TX N3b M0 IIIC TX N3c M0 IIIC TX NX M0 UNK TX N0 M1 IV TX N0(i-) M1 IV TX N0(i+) M1 IV TX N0(mol-) M1 IV TX N0(mol+) M1 IV TX N1 M1 IV TX N1NOS M1 IV TX N1a M1 IV TX N1b M1 IV TX N1c M1 IV TX N1mi M1 IV TX N2NOS M1 IV TX N2a M1 IV TX N2b M1 IV TX N3NOS M1 IV TX N3a M1 IV TX N3b M1 IV TX N3c M1 IV TX NX M1 IV TX N0 MX UNK TX N0(i-) MX UNK TX N0(i+) MX UNK TX N0(mol-) MX UNK TX N0(mol+) MX UNK TX N1 MX UNK TX N1NOS MX UNK TX N1a MX UNK TX N1b MX UNK TX N1c MX UNK TX N1mi MX UNK TX N2NOS MX UNK TX N2a MX UNK TX N2b MX UNK TX N3NOS MX UNK TX N3a MX UNK TX N3b MX UNK TX N3c MX UNK TX NX MX UNK &commonsummarystage; Extension Size Table For CS Extension codes 100-140, 200, and 300 ONLY, the T category for AJCC 6 and AJCC 7 staging is assigned based on the value of CS Tumor Size, as shown in the this table. A CS Tumor Size code takes precedence over a CS Extension "stated as T" code; however, if CS Tumor Size is coded as unknown, the T category may be assigned based on "stated as T" recorded in CS Extension. CS Tumor Size CS Extension 100 100 CS Extension 110 110 CS Extension 120 120 CS Extension 130 130 CS Extension 140 140 CS Extension 200 200 CS Extension 300 300 000 ERROR ERROR ERROR ERROR ERROR ERROR ERROR 001 T1mi T1mi T1mi T1mi T1mi T1mi T1mi 002-005 T1a T1a T1a T1a T1a T1a T1a 006-010 T1b T1b T1b T1b T1b T1b T1b 011-020 T1c T1c T1c T1c T1c T1c T1c 021-050 T2 T2 T2 T2 T2 T2 T2 051-989 T3 T3 T3 T3 T3 T3 T3 990 T1mi T1mi T1mi T1mi T1mi T1mi T1mi 991 T1b T1b T1b T1b T1b T1b T1b 992 T1NOS T1NOS T1NOS T1NOS T1NOS T1NOS T1NOS 993-995 T2 T2 T2 T2 T2 T2 T2 996 T1NOS T1NOS T1NOS T1NOS T1NOS T1NOS T1NOS 997 ERROR ERROR ERROR ERROR ERROR ERROR ERROR 998 T3 T3 T3 T3 T3 T3 T3 999 TX T1mi T1a T1b T1c TX TX Extension Behavior Table Note: For CS Extension codes 050 and 070 ONLY, Summary Stage 1977 and Summary Stage 2000 are assigned based on the value of Behavior Code ICD-0-3, as shown in this table. Behavior Code ICD-O-3 SS77 SS2000 Comment 0 ERROR ERROR Behavior code of 0 should not be used with CS Extension code 050 or 070. 1 ERROR ERROR Behavior code of 1 should not be used with CS Extension code 050 or 070. 2 IS IS 3 L L Lymph Nodes Positive Axillary Node Table Note: This table is used when CS Reg Nodes Eval is not coded and CS Lymph Nodes is coded 250, 258, 260, 280, 500, 510, 520, 600, 610, 620, 630, 720, or 748 ONLY. The N category is assigned based on the value of CS Lymph Nodes and the value of CS Site-Specific Factor 3, Number of Positive Ipsilateral Axillary Lymph Nodes. CS Lymph Nodes CS SSF 3 000 0 CS SSF 3 001-003 1 3 CS SSF 3 004-009 4 9 CS SSF 3 010-090 10 90 CS SSF 3 095 95 CS SSF 3 097 97 CS SSF 3 098 98 CS SSF 3 099 99 CS SSF 3 988 988 250 N1 N1a N2a N3a N1a N1a N1 N1 ERROR 258 N1NOS N1NOS N2a N3a N1NOS N1NOS N1NOS N1NOS ERROR 260 N1 N1NOS N2a N3a N1NOS N1NOS N1NOS N1NOS ERROR 280 N2NOS N2NOS N2NOS N3a N2NOS N2NOS N2NOS N2NOS ERROR 500 N2a N1a N2a N3a N1a N1a N2a N2a ERROR 510 N2a N2a N2a N2a N2a N2a N2a N2a ERROR 520 N1NOS N1a N2a N3a N1a N1a N1a N1a ERROR 600 N1 N1a N2a N3a N1 N1a N1 N1 ERROR 610 N2NOS N2NOS N2NOS N2NOS N2NOS N2NOS N2NOS N2NOS ERROR 620 N2NOS N2NOS N2NOS N3a N2NOS N2NOS N2NOS N2NOS ERROR 630 N2NOS N2NOS N2NOS N3a N2NOS N2NOS N2NOS N2NOS ERROR 720 N1c N1c N3b N3b N1c N1c N1c N1c ERROR 748 N2b N2b N3b N3b N2b N2b N2b N2b ERROR IHC MOL Table Note: For CS Lymph Nodes code 000 ONLY, the N category is based on the value of CS Site-Specific Factor 4, IHC of Regional Lymph Nodes, and CS Site-Specific Factor 5, Molecular Studies of Regional Lymph Nodes, as shown in this table: CS SSF 4 IHC CS SSF 5 MOL 000 0 CS SSF 5 MOL 001 1 CS SSF 5 MOL 002 2 CS SSF 5 MOL 888 888 CS SSF 5 MOL 987 987 CS SSF 5 MOL 988 988 000 N0 N0(mol-) N0(mol+) ERROR ERROR ERROR 001 N0(i-) N0(i-) N0(mol+) ERROR ERROR ERROR 002 N0(i+) N0(i+) N0(i+) ERROR ERROR ERROR 009 N0(i+) N0(i+) N0(i+) ERROR ERROR ERROR 888 ERROR ERROR ERROR ERROR ERROR ERROR 987 ERROR ERROR ERROR ERROR ERROR ERROR 988 ERROR ERROR ERROR ERROR ERROR ERROR Lymph Nodes Pathologic Evaluation Table Note: This table is used when CS Lymph Nodes Eval is coded 2 (p), 3 (p), 6 (yp), or 8 (a) and CS Lymph Nodes is coded 250, 258, 260, 280, 500, 510,520, 600, 610, 620, 630, 720, or 748 ONLY. The N category is assigned based on the value of CS Lymph Nodes and the value of CS Site-Specific Factor 3, Number of Positive Ipsilateral Axillary Lymph Nodes. CS Lymph Nodes CS SSF 3 000 0 CS SSF 3 001-003 1 3 CS SSF 3 004-009 4 9 CS SSF 3 010-090 10 90 CS SSF 3 095 95 CS SSF 3 097 97 CS SSF3 098 98 CS SSF 3 099 99 CS SSF 3 988 988 250 N1NOS N1a N2a N3a N1NOS N1NOS N1NOS N1NOS ERROR 258 N1NOS N1NOS N2a N3a N1NOS N1NOS N1NOS N1NOS ERROR 260 N1NOS N1a N2a N3a N1NOS N1NOS N1NOS N1NOS ERROR 280 N2NOS N2NOS N2NOS N3a N2NOS N2NOS N2NOS N2NOS ERROR 500 N1NOS N1a N2a N3a N1NOS N1NOS N1NOS N1NOS ERROR 510 ERROR ERROR ERROR ERROR ERROR ERROR ERROR ERROR ERROR 520 N1NOS N1a N2a N3a N1NOS N1NOS N1NOS N1NOS ERROR 600 N1NOS N1a N2a N3a N1NOS N1NOS N1NOS N1NOS ERROR 610 ERROR ERROR ERROR ERROR ERROR ERROR ERROR ERROR ERROR 620 N2NOS N2NOS N2NOS N3a N2NOS N2NOS N2NOS N2NOS ERROR 630 N2NOS N2NOS N2NOS N3a N2NOS N2NOS N2NOS N2NOS ERROR 720 N1c N1c N3b N3b N1c N1c N1c N1c ERROR 748 N2b N2b N2b N3a N2b N2b N2b N2b ERROR Lymph Nodes Clinical Evaluation Table Note: This table is used when CS Lymph Nodes Eval is coded 0 (c), 1 (c), 5 (c), or 9 (c) and CS Lymph Nodes is coded 250, 258, 260, 280,500, 510, 520,600, 610, 620, 630, 720 or 748ONLY. The N category is assigned based on the value of CS Lymph Nodes and the value of CS Site-Specific Factor 3, Number of Positive Ipsilateral Axillary Lymph Nodes. CS Lymph Nodes CS SSF 3 000-099 0 99 CS SSF 3 988 988 250 ERROR ERROR 258 ERROR ERROR 260 N1 ERROR 280 N2NOS ERROR 500 N2a ERROR 510 N2a ERROR 520 ERROR ERROR 600 N1 ERROR 610 N2NOS ERROR 620 ERROR ERROR 630 N2NOS ERROR 720 ERROR ERROR 748 N2b ERROR